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ABSTRACT 
Recognizing the substantial public health impact of tobacco dependence (TD) and 
consequent importance of reducing tobacco use, the United States Public Health 
Service (USPHS) issues evidence based clinical practice guidelines (CPG) that urge 
“clinicians and health care delivery systems to consistently identify and document 
tobacco use status and treat every tobacco user seen in a health care setting”. The 
latest guidelines, published in 2008, were written “in response to new, effective 
clinical treatments for tobacco dependence” identified since 1999 and contain 
strategies and recommendations designed to assist clinicians, administrators, insurers, 
and purchasers in “delivering and supporting effective treatments for tobacco use and 
dependence”.  The guidelines state that, barring contraindication or insufficient study 
in a specific sub-group, interventions for tobacco cessation are appropriate for all 
individuals who use tobacco, including patients with medical co-morbidities.  Specific 
medical co-morbidities cited in the CPG for which pharmacologic interventions have 
been shown effective include cancer.  Moreover, continued smoking in cancer patients 
can affect the pharmacokinetics of cancer treatments. 
An important consideration for patients selected for treatment with smoking 
cessation medication (SCM) is the duration of therapy or persistence with therapy as 
these measures of medication adherence have been found to be associated with 
treatment success in clinical trials.  Another important factor to consider in assessing 
SCM is recognition that tobacco dependence is a chronic disease that often requires 
repeated interventions.  Patient relapse to tobacco use following a period of abstinence 
achieved with use of SCM is not unexpected.  
  
Since the CPG serve as the definitive source to inform tobacco cessation practice 
in the US, one would expect that epidemiologic studies of smoking cessation 
medications (SCM) have been conducted in order to understand intervention use in 
routine clinical practice, both in the overall population of tobacco dependent patients 
and those with smoking related co-morbidities, such as cancer since epidemiologic 
studies are a required early step in the process toward closing gaps in care. 
However, literature search for population level studies in large representative 
populations revealed few and most are derived from survey level data.  Similarly, 
literature search for studies of the use of SCM in patients with cancer returned few 
results.   Thus, real world studies describing the epidemiology of SCM in routine US 
clinical practice are lacking.  Though they are not without limitations, adequately 
controlled observational studies using administrative healthcare claims data can 
answer important questions in a relatively inexpensive and time-efficient manner.   
This dissertation utilizes the manuscript format and has three main objectives: 
 
1) To describe the pharmacoepidemiology of SCM among smokers identified 
through CPT and ICD-9 codes to answer the question, “Who among smokers receives 
pharmacologic treatment?” 
2) To describe treatment persistence in tobacco dependent patients prescribed 
SCM, repeat treatment with SCM and patient and prescriber characteristics associated 
premature discontinuation and repeat therapy. 
  
3) Evaluation of the use of SCM among tobacco dependent patients with smoking 
related cancer diagnoses to answer the question, “Who receives pharmacologic 
treatment and who doesn’t?” 
The LifeLink™ Helath Plan Claims Database was employed to identify patients 
diagnosed or counseled for tobacco cessation (index) during a one year period and 
evaluate the use of SCM in the 1 year following the index date, rates of premature 
discontinuation and repeat therapy as well as use of SCM in patients with smoking 
related cancers.  Predictors of the use of SCM in tobacco dependent patients, 
premature discontinuation and repeat therapy were assessed using logistic regression 
models, controlling for pre-index patient and/or treatment characteristics.  The same 
was performed to identify predictors of SCM use in tobacco dependent patients with 
smoking related cancer. 
Major findings reported in the first manuscript are that approximately 11% of 
newly diagnosed tobacco dependent patients received treatment within a year of 
diagnosis and that the youngest and oldest age groups were less likely to receive SCM 
than those at middle age.  Of note, patients who may have had tobacco related co-
morbidities were less likely to receive treatment than those without.  The study of 
persistence and repeat therapy revealed that mean persistence was 36 days and that 
>90% of patients discontinued SCM before 12 weeks of therapy, shorter than 
recommendations.  Patients under 50 years old and 65 years or older were more likely 
to discontinue prematuredly than patients aged 50-58 years.  Few patients (5%) 
repeated therapy ≥ 26 weeks following index.  The final study of the use of SCM in 
tobacco dependent patients with smoking related cancer revealed that tobacco 
  
dependence of counseling/advice for smoking cessation in these patients was likely 
coincident or following diagnosis of comorbidity.  This finding was also noted in the 
first study where pre-index mean Charlson Comorbidity was lower than the period 
following diagnosis.  
The 3 studies presented provide insight into the utility of using administrative 
claims data to study patients who are tobacco dependent and their treatment with 
SCM.  Taken in their entirety, these studies’ findings contribute certain apparent 
overarching themes and other important observations that may be useful to practicing 
clinicians to highlight potential opportunities for treatment with SCM in patients who 
may benefit most.  First, it seems that the health system is identifying patients as 
tobacco dependent co-incident with identification of other co-morbidity.  Earlier 
intervention of management of tobacco dependence is likely the best strategy to aid 
patients in quitting.  Second, diagnosis or counseling by a hospital related practitioner 
was associated with reduced likelihood of SCM treatment as an outpatient overall and 
in patients with smoking related cancer.  Hospitalization has been identified as an 
opportune time for clinicians to intervene and offer assistance with smoking cessation.  
Diagnosis by a therapeutic specialist was associated with lower likelihood of SCM use 
and tobacco dependence can be a major contributor to risk of events often managed by 
therapeutic area specialists, e.g., cardiologists and oncologists.  Rates of treatment 
with SCM by physician type is not widely described but literature reports and clinical 
practice guidelines recommend that cardiologists and oncologists are well positioned 
to assist patients in their quit attempts to reduce overall health risks.  
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PREFACE 
This thesis was written and formatted following the guidelines presented by the 
University of Rhode Island Graduate School.  It is written in the Manuscript Format 
and is organized in three chapters:  Epidemiology of smoking cessation medications in 
the United States (Chapter 1), Persistence and Repeat Use of Smoking Cessation 
Medications in the United States (Chapter 2), Use of Smoking Cessation Medications 
in Tobacco Dependent Patients with Smoking Related Cancers (Chapter 3). 
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Background 
Smoking continues to be a leading contributor to morbidity and mortality in the 
United States1,2(US)  and intensive public health campaigns have been waged to assist 
smokers’ quitting efforts and to educate clinicians as to the chronic relapsing nature of 
tobacco dependence and assist their efforts in aiding their patients to quit.  Leading US 
based clinical practice guidelines for tobacco cessation recommend that smoking 
cessation medications (SCM) be offered to all patients, excepting those with specific 
contraindications or where evidence of efficacy may be lacking.3  Despite these broad 
recommendations for employing SCM to aid smokers in quitting, little is known as to 
the extent of their use, nor which patient characteristics may be associated with 
prescription of such treatments. 
 Health-related databases, including claims databases, are an important data 
source for research.  One strength of these data is that they allow researchers to 
examine medical care utilization as it occurs in routine clinical care or the “real 
world”.  These data sources can provide large study populations, long observation 
periods and allow for examination of specific sub-populations.4   Though they are not 
without limitations, adequately controlled observational studies using administrative 
claims data can answer important questions in a relatively inexpensive and time-
efficient manner.4   Of note, current estimates suggest that 87% of the US population 
has health insurance coverage through employer sponsorship (48%), other private 
insurance (6%) , Medicaid (16%), Medicare (15%) or other public insurance (2%).5   
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Consequently, examination of nationwide US health plan data is expected to 
reveal useful information regarding tobacco cessation treatment in routine clinical 
practice.  Few reports exist in the literature regarding the epidemiology of tobacco 
cessation therapy in routine US clinical practice.   Studies with a national focus 
include those using national survey databases such as the National Health Interview 
Survey and the National Ambulatory Medical Care Survey.6-8  Similar to Healthcare 
Effectiveness Data and Information Set (HEDIS) measures, these databases typically 
include self-reported smokers’ recall of whether assistance or advice to quit smoking 
was given by a health care provider.  Although these studies provide a broad 
epidemiologic perspective, their results may be affected by recall bias. 
Few studies have examined administrative claims data for the purpose of 
understanding SCM use and examples include studies specific to varenicline and the 
effect of a utilization management approach and patients’ copay on future dispensing 
of any SCM.9,10  The aims of this research were to describe the 
pharmacoepidemiology of SCM in newly identified tobacco dependent patients in 
routine clinical practice in the US and to assess the patient and provider characteristics 
associated with its prescribing. 
Methods 
This study employed a retrospective cohort design using de-identified data from 
the LifeLink™ Health Plan Claims Database (formerly known as Pharmetrics) which 
is comprised of commercial health plan information obtained from managed care plans 
throughout the US.  It is fully adjudicated medical and pharmaceutical claims for over 
68 million unique patients from over 102 health plans across the U.S. (approximately 
 4 
 
16 million covered lives per year).  The database includes both inpatient and 
outpatient diagnoses (In International Classification of Diseases, Ninth Revision, 
Clinical Modification [ICD-9-CM] format) and procedures (in Current Procedure 
Terminology [CPT-4] codes and Healthcare Common Procedure Coding System 
[HCPCS] formats) as well as both retail and mail order prescription records.  
Available data on prescription records include the National Drug Code (NDC) as well 
as the quantity of the medication dispensed.  Charge, allowed and paid amounts are 
available for all services rendered, as well as dates of service for all claims.  
Additional data elements include demographic variables (age, gender, geographic 
region), insurance product type (e.g., HMO, PPO), payer type (e.g., commercial, self-
pay), provider specialty, and start and stop dates of health-plan enrollment.   
 
The sample consisted of patients aged 16-76 with a diagnosis code for tobacco use 
disorder and/or CPT code for tobacco cessation counseling or advice (Appendix) 
during the period July 2010 to June 2011 (index) (n=15,000).  Patients with ICD-9, 
CPT codes, or prescriptions related to tobacco dependence or treatment in the 
lookback period January 2009 through June 2010 were excluded.   Pre-index Charlson 
Comorbidity Index (CCI) scores for each patient were calculated using the algorithm 
develop by Quan, et al., through identification of ICD-9 codes related to 17 
co-morbidity categories in the 12 month period prior to and 12 month period following 
the index date (including index date) (Appendix).   Weights specific to each co-
morbidity category were assigned and the CCI score calculated; higher scores indicate 
greater co-morbidity.11   
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Statistical Analysis  
Descriptive statistics were used to describe demographic and clinical 
characteristics and frequency of prescription of SCM defined as 1 or more claim for 
varenicline, bupropion SR or NRT during the 1 year period following diagnosis for 
tobacco use disorder or CPT code for tobacco cessation counseling, advice or 
treatment. Demographic characteristics included patient age at index, gender, 
geographic region of residence and insurance related factors such as payer type and 
insurance product.  Clinical characteristics included 12 months pre-index CCI score 
and CCI categories.  Provider characteristics included the practitioner type associated 
with diagnosis of or counseling/advice for tobacco dependence. 
 
Patients were categorized into one of two groups, those who were prescribed SCM 
within 1 year of diagnosis and those who were not.  Bivariate analyses including t-
tests for continuous variables and chi-square tests or Fisher’s Exact test for categorical 
variables were used to analyze differences in characteristics of those patients receiving 
SCM and those who did not.  Assessment of factors associated with SCM prescription 
was performed by conducting a series of univariate logistic regression equations.  To 
qualify for multivariate logistic regression, variables had to be associated with SCM 
prescription in the univariate analyses (p<0.2) or be otherwise clinically important.  
Multivariate logistic regression was used to assess relationships between the 
independent variables of patient and provider characteristics and the dependent 
variable of pharmacologic intervention for SC within a 1 year period following the 
diagnosis of or procedure for tobacco use disorder.  The model was created using a 
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backward elimination process and the likelihood ratio test and AIC used to assess the 
model at each step, removing least statistically significant covariates (p>0.05) with 
each iteration and evaluating differences between full and reduced models for 
statistical significance.  In advance of model inclusion, parametric form of continuous 
independent variables and multicollinearity among independent variables were 
assessed.   
Multicollinearity was assessed by regressing independent variables against the 
independent variable of patient age at index.  Main effects and two factor interactions 
of independent variables found significant in the model were assessed.  The Hosmer-
Lemeshow test was used to assess goodness of fit of the final model.  The measure of 
effect is presented as an odds ratio with corresponding 95% confidence intervals. All 
analyses were conducted using SAS® Version 9.4 (SAS Institute, Cary, NC) with 
statistical significance defined as p <0.05.  Analyses were performed using a 2-tailed 
alpha of 0.05 and 95% confidence intervals calculated. 
 
Results  
In total, 15,000 patients with ICD-9 or CPT codes indicative of tobacco 
dependence disorder were identified (Figure 1).  Mean (SD) age at diagnosis was 
46.08 (14.46) years, 54.49% were female and 70.60% resided in the Midwest.  (Table 
1).  Mean (SD) pre-index Charlson Co-morbidity Index (CCI) was 0.540 (±1.184) 
with most patients having no Charlson co-morbidity (70.73%) and, of those with co-
morbidity, the most frequently observed was COPD (12.61%). Most (56.95%) were 
diagnosed with or counseled for tobacco cessation by a general medicine practitioner 
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and the majority of patients (79.27%) had commercial insurance (s 1,2).  Of the 
diagnosed sample, 1,621 (10.81%) had a prescription for SCM filled during the 1 year 
post-index period (Figure 1).   Varenicline was the most commonly prescribed agent 
(69.46%) and bupropion SR the least commonly prescribed (4.38%), with NRT 
formulations comprising 27.76% of SCM use (Figure 2).  
In treated patients, mean (SD) age was 44.56 (12.52) years and the youngest and 
oldest patients were least likely to be prescribed SCM while those aged 25-44 were 
nearly twice as likely to receive SCM.   Gender and geographic region were also 
related to receiving SCM with females being more likely than males to have a  
prescription for SCM (11.33% vs. 10.18%, p=0.0243) and patients residing in the 
Midwest nearly 3 times more likely to receive SCM than those residing in the West.  
Pre-index mean CCI score was lower in SCM treated patients than untreated (0.402 vs. 
0.5571, p<0.0001) with SCM treatment occurring in >20% of tobacco dependent 
patients with HIV/AIDS and approximately 10% of COPD patients.  Less than 10% of 
patients with   other CCI categories received treatment.  Patients with commercial and 
Medicaid insurance types had the highest treatment rates (11.74% and 12.56%, 
respectively) with <10% of patients with Medicare Supplemental or Medicare 
Advantage receiving treatment.    
 
The most common diagnosing practitioner type was the category of general 
medicine (56.95%) and more patients (14.35%) were treated with SCM who were 
diagnosed as tobacco dependent by a general medicine practitioner than any other 
specialty.  The lowest rates  of SCM treatment patients were in those whose diagnosis 
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was made by a hospital related physician (4.92%) or a therapeutic area specialist 
(7.06%), though these were the second and third most common diagnosing practitioner 
types (35.23% and 9.83%, respectively) (Table 3).   
Multivariate logistic regression results indicated that patients with a pre-index co-
morbidity of cancer had reduced odds of receiving SC medication (OR 0.703, 95% CI 
0.504-0.980). Compared to patients age 45-54, patients between 18-24 years had lower 
likelihood of receiving SCM ( OR 0.539, 95% CI 0.430-0.677)  as did  patients >56 
years (OR 0.616, 95% CI 0.528-0.718).  Compared to those patients diagnosed by a 
general medicine practitioner, those diagnosed or counseled for tobacco dependence 
by a hospital related practitioner (OR 0.332, 95% CI 0.285-0.386), by a therapeutic 
area specialist (OR 0.594, 95% CI 0.473-0.745) had lower likelihood of SC 
medication prescription (Table 4).  We found no association of gender, geographic 
region or insurance related factors with prescription of SCM in the 1 year post-index.  
Once you have the correct amount of content on the first page, you can then move 
your cursor onto the next page of the template and add the rest of the content of the 
chapter by either typing or copying and pasting.   
 
Discussion      
Clinical practice guidelines for tobacco cessation recommend that SCM be 
offered to all tobacco dependent patients with few exceptions.  However, little 
information exists regarding the extent of SCM use in broad populations of tobacco 
dependent persons in the US.  This study observed that approximately 11% of those 
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diagnosed or counseled for tobacco cessation (10.18% of males, 11.3% of 
females) were prescribed SCM during the following year and the mean age (~46 
years) was slightly older than or similar to that studied in recent clinical trials of SCM. 
12 13 14   After controlling for covariates, the patient demographics of gender and 
geographic region were not associated with SCM treatment. However, 18-24 and 56-
75 year olds had lower odds of receiving SCM than those aged 45-54, the age group 
with the largest proportion of treated patients.  Of note, the clinical factor of comorbid 
cancer had a negative association, as did clinical settings of diagnosis other than 
general medicine.   
It is difficult to compare rates of SCM prescribing and recipient patient 
characteristics to those reported in the current literature due to dissimilar study designs 
and populations studied, however comparison of results from some studies is worth 
noting.  Huang, et al 15 used association rule mining methods to identify smokers in 
the United Kingdom (UK) primary care and the characteristics of those who typically 
do or do not receive SCM.  The authors identified a population of smokers that was 
46.7% male, of which 13.4% received a prescription for one or more SCM in 2008; 
12.8% of males received SCM and 13.9% of females.  Contrary to our finding that 
gender was not associated with receipt of treatment, these authors found that females 
were slightly more likely than males to receive SCM in multivariate analysis (OR 
1.09, 95% CI 1.06-1.11).  ).  They also found that those in age groups > 30 years were 
more likely to receive SCM than younger patients.  Similarly, we found that the 
youngest patients (<24 years) were less likely to receive SCM than those patients age 
45-54, however we also found that the oldest patients (>56 years) had lower odds.  Of 
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note, a recent policy statement by the American Academy of Pediatrics states that, 
despite limited research in this age group, SCM is an option for tobacco-dependent 
adolescents based on level of dependence and readiness to change.16 Also of note is a 
recent literature review of SCM in older adults in which the authors report a dearth of 
information regarding use in this population.17 More study of the use in SCM in the 
youngest and oldest tobacco dependent patients is needed.  
In the current study, patients with Medicaid and commercial insurance (primarily 
employer base) had the highest rates of SCM use (12.56% and 11.74%, respectively) 
while patients with Medicare Advantage had the lowest rate (5.08%).  It should be 
noted that during the study period, Medicare coverage of tobacco cessation services 
may have been limited.  In 2011, Medicare expanded coverage of tobacco cessation 
counseling to any Medicare recipient who wanted to quit.  Before then, these services 
were limited to those who had a smoking-related illness or symptoms of such an 
illness.  Similar rates of pharmacy benefit (83.5%) as rates of commercial insurance 
(~79.3%) were observed in this study and, while coverage specific to SCM is not 
known, patients with a pharmacy benefit may be more likely to fill prescriptions than 
those without.   
Medicaid populations have a higher smoking rate than the general population18,19 
which might explain higher treatment rates than other payer types.  In addition, 
coverage for SCM in Medicaid may be different than in other payer types.  As of 
2014, some SCM for some Medicaid enrollees were covered by all 50 states and the 
District of Columbia, but coverage for all  approved SCM products for all enrollees 
was available in only 7 states. 20 Of note, in 2006, Massachusetts expanded coverage 
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to include behavioral counseling and all FDA approved medications for tobacco 
cessation for the Massachusetts Medicaid population and researchers found a decrease 
in crude smoking rate after benefit initiation.21 
Overall, comorbidity as assessed by CCI was low but mean CCI score was higher 
in the follow up period compared to the 12 months pre-index.  Mean pre-index CCI 
was 0.540 and this increased by 34% to 0.724 in the follow up period.  While still low, 
the higher score in the follow up period suggests that diagnosis of or counseling for 
tobacco cessation may have been coincident with a tobacco related diagnosis or other 
health event.  Additionally, the absence of any Charlson comorbidity pre-index was 
observed in 70.73% of patients, but this proportion was lower in the follow up period 
(60.55%) suggesting that diagnosis of a clinically significant event took place on or 
following the index event.  Of note, certain Charlson categories were observed at 
considerably higher rates in the follow up period only as compared to pre-index only, 
e.g., COPD (4.7% pre-index only, 11.05% in follow-up only) and MI (0.59%  pre-
index only, 1.57% in follow-up only) (data not shown). This trend suggests that 
diagnosis of COPD or MI may lead practitioners to subsequently code for tobacco 
dependence.   
We found that patients with pre-index diagnosis of HIV had the highest rates of 
SCM prescription while those with MI had the lowest. Individuals who are HIV-
positive are more likely to smoke than the general population and HIV-positive 
smokers have higher mortality rates and greater likelihood of infectious comorbidities 
than HIV-positive non-smokers.22-27  In addition, daily tobacco may possibly attenuate 
the immune and virological response to antiretroviral therapies.28 The finding of high 
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rates of SCM use in patients with HIV-AIDS diagnosis in the present study reflects 
clinician recognition of particular risk of tobacco dependence in these patients.  In 
contrast, the low rate of SCM prescribing in patients with MI diagnosis at baseline  
was surprising as stopping smoking after MI is one of the most effective actions for 
secondary prevention of CVD 29. Others have described tobacco use as the forgotten 
cardiac risk factor, its treatment possibly receiving less attention than treatment of 
hypertension, hyperlipidemia or diabetes.29 30 
Our finding that a pre-index cancer diagnosis was associated with lower 
likelihood of receiving SCM is worth discussion.  The USPHS reports cancer as a 
comorbidity in which SCM has been demonstrated as beneficial.3  Health benefits can 
results from smoking cessation after a cancer diagnosis at any stage or prognosis and 
National Comprehensive Cancer Network (NCCN) recommends that treatment plans 
for smokers with cancer include pharmacotherapy as an option for intervention.31  Of 
note, results of a survey by Warren et al report that physicians caring for lung cancer 
patients believe that current smoking affects outcomes and that tobacco cessation is a 
necessary part of clinical care, but few provide assistance to their patients as a routine 
part of cancer care.32  Our results underscore the possible opportunity to study use and 
timing of SCM prescribing in patients with cancer.  
Stratification of patients prescribed SCM by physician type (those diagnosing 
their tobacco dependence)  revealed some interesting findings.  The most common 
diagnosing specialty was the category of general medicine (56.95%) and more patients 
(14.35%) were treated with SCM who were diagnosed as tobacco dependent by a 
general medicine practitioner than any other specialty.  The lowest proportions of 
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SCM treated patients were those whose diagnosis was made by a hospital related 
physician (4.92%) or a therapeutic specialist (7.06%), though these were the second 
and third most common diagnosing specialty (35.23% and 9.83%, respectively).  
Encounters with hospital related practitioners has been identified as a teachable 
moment to motivate individuals to risk reducing behaviors such as smoking 
cessation33   
Hospitalization is an opportunity for patients to attempt to quit tobacco as they are 
likely to be in a smoke-free environment and may be particularly motivated by an 
illness caused or exacerbated by tobacco use (Fiore 2008).  Patients can be encouraged 
to remain smoke free after discharge and begin treatment in the hospital. In a meta-
analysis of randomized controlled trials of smokers hospitalized for a CVD diagnosis, 
a smoking cessation intervention begun in the hospital and sustained for at least 1 
month post-discharge, increased cessation rates by 42% (RR: 1.42, 95% CI: 1.29–
1.56) 6–12 months post-discharge and starting NRT in hospital increased quit rates 
over counselling alone.34  Furthermore, in a trial of smokers hospitalized with MI, 
compared to usual care, intensive intervention with counseling and pharmacotherapy 
increased cessation rates and reduced all-cause mortality and hospital readmission.35  
Furthermore, compared to diagnosis made by general medicine practitioner, 
patients diagnosed by any other practitioner type had lower odds of SCM prescription.  
Rates of treatment with SCM by physician type is not widely described, however 
Rigotti, et al state that cardiologists have a special opportunity to promote cessation 
since a smoker receiving a diagnosis of CHD may see the health risks of smoking 
suddenly personally salient and be motivated to reduce future risk. 29  As described 
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above, the NCCN recommends the same importance of fostering smoking cessation by 
oncologists.  It should be noted that a patient may have received a diagnosis by 
multiple specialties on the same date, indicating multiple interactions with the health 
care system on the same date and possibly suggestive of the occurrence of an event. 
This study utilized data from medical and pharmacy claims which are collected 
for billing and reimbursement purposes and which have inherent limitations. We used 
ICD-9-CM and tobacco cessation counseling specific CPT and HCPCS codes to 
identify smokers, excluding those with these and SCM codes in the 12 months pre-
index. While this method may under-estimate the number of smokers and SCM treated 
patients, use of ICD-9-CM codes to identify smokers has been validated previously 
and the utility of administrative claims to describe SCM demonstrated.36,9,10  The use 
of prescription claims exclusively in the current study may have missed the use of 
over the counter (OTC) products, but in an US insured population, over the counter 
SCM may be covered under the pharmacy benefit. It is difficult to estimate the extent 
to which OTC NRT is used, but results of an international survey of smokers using 
SCM in a quit attempt indicated that 68.3% of subjects self-report OTC NRT use.  Of 
note, those who obtained OTC NRT appeared more likely to discontinue in the first 
week of use than those receiving NRT by prescription (23% vs. 13.4%, respectively.37  
As mentioned above, description of SCM coverage by Medicaid is often publicly 
available, but coverage by private health plans is not as widely reported and benefit 
designs can change frequently.  However, a survey of Tennessee health plans yields 
some insight where researchers found wide variation in coverage of prescription and 
over-the counter medications with bupropion covered most often, followed by 
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varenicline, NRT patches and gum, then other forms of NRT.  Given that the 
Affordable Care Act requires all new private health insurance plans to cover services 
recommended by the US Preventative Services Task Force including tobacco 
cessation treatments, future study using administrative data may yield different results.  
Moreover, evolution of reimbursement to incentivize physicians to intervene to aid 
tobacco cessation may lead to increased use of coding over time.  Although data used 
in this study were collected from all U.S. census regions, due to geographic biases, 
any unprojected geographic information may not be representative of the true 
distribution.  Finally, the small number of patients in some subgroups evaluated 
precludes comparisons by statistical analysis and thus, results are descriptive in nature.  
It is important to note that though patients were identified as smokers through 
diagnosis or procedure codes, this provides no insight into readiness to quit which is 
an important component of cessation attempts.3   
Despite these limitations, this study adds important information regarding the 
epidemiology of the use of SCM in the U.S.  Specifically, despite guidance describing 
pharmacotherapy as an option to aid most patients in quitting, approximately 11% of 
newly diagnosed tobacco dependent patients received treatment within a year of 
diagnosis,  and the youngest and oldest patients were less likely to receive SCM than 
those at middle age. Additionally, the lowest proportions of SCM treated patients were 
those whose tobacco dependence diagnosis was made by a hospital related physician.  
Perhaps the most concerning finding was that patients with possibly tobacco related 
co-morbidities are less likely to receive treatment than those without.  These findings 
suggest opportunity for more focused research with regard to use and timing of SCM 
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in these at risk populations. In addition to the findings regarding the epidemiology of 
SCM, this study suggests that diagnosis or procedure for tobacco dependence took 
place co-incident with occurrence of another co-morbidity and also suggests further 
study in the areas of systematic and early documentation of tobacco dependence which 
may facilitate earlier intervention.   
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Table 1.1.  Rate of SCM Prescribing by Demographic Characteristics among 
Patients Diagnosed with Tobacco Dependence,  LifeLink™ Health Plan Claims 
Database,        (July 2010-June 2011)  
Rx=dispensed prescription, HMO=health maintenance organization, POS=place of service, 
PPO=preferred provider organization, SD=standard deviation, yr-year, No. = number                        
 
Total   
(N = 15,000) 
 
No Rx for SCM in 1 
yr follow up 
(n=13,379) 
Rx for SCM in 1 
yr follow up 
(n=1,621) 
 
p-value 
Age at index, 
years, mean, 
(SD)  
46.08 (± 14.46) 
46.27 (14.67) 44.56 (12.52)  
<0.0001 
Age Category, No. (%)  
 
 
 
<0.0001 
 
 
 
 
    
18-24 1,598 (10.65) 1491 (93.30) 108 (6.76) 
25-34 1,984 (13.23) 1700(85.69) 284 (14.31) 
35-44 2,590 (17.27) 2233 (86.22) 357 (13.78) 
45-54 3,965 (26.43) 3475 (87.64) 490 (12.36) 
55-64 3,533 (23.55) 3219 (91.11) 314 (8.89) 
65-75 1,283 (8.55) 1217 (94.85) 65 (5.07) 
Gender, No. (%)  
Female 8,174 (54.49) 
7248(88.67) 926 ( 11.33) 0.0243 
Male 6,826 (45.51) 6131 (89.82) 695  (10.18) 
Patient Geographic Region, No. (%) 
East 1,577 (10.51) 1403 (88.97) 174 (11.03)  
 
<0.0001 Midwest 10,590 (70.60) 9254 (87.38) 1337 (12.62)  
South 76 (0.51) ≤75 (≤98.68)  ≤5 (≤6.58) 
West 2,757 (18.38) 2647 (96.01) 110 (3.99) 
Payer Type/Benefit Design, No. (%) 
Consumer 
Directed 527 (3.51) 
459 (87.10) 68 (12.90)  
0.1145 
HMO   10,342 (68.95) 
9212 (89.07) 
 
1130 (10.93)  
0.4818 
Indemnity   208 (1.39) 188 (90.38) 20 (9.62) 0.5773 
POS   6,383 (42.55) 5589 (87.56) 794 (12.44) <0.0001 
PPO   1,133 (7.55) 1038 (91.62) 95 (8.38) 0.0063 
   
Commercial 11,890 (79.27) 
10494 (88.26) 1396 (11.74) <0.0001 
Medicaid   2054 (13.69) 
1796 (87.44) 
 
258 (12.56) 0.0058 
Medicare 
Supplemental  452 (3.01) 
416 (92.04) 36  (7.96) 0.0481 
Medicare 
Advantage  413 (2.75) 
392 (94.92) 21  (5.08) 0.0001 
Self-insured   1832 (12.21) 1702 (92.90) 130 (7.10) <0.0001 
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Table 1.2. Rate of  SCM use by Clinical Characteristics in  Patients Diagnosed 
with Tobacco Dependence, LifeLink™ Health Plan Claims Database  (July 2010-
June 2011)                          
Rx=dispensed prescription, CCI=Charlson Co-morbidity Index, HIV/AIDS=Human immunodeficiency 
Virus/Acquired Immune Deficiency Syndrome 
 
 
 
 
 
 Total (N=15,000) 
No Rx for SCM 
in 1 yr follow up 
(n=13,379) 
Rx for SCM in 1 
yr follow up 
(n=1,621) 
p-value 
No CCI co-
morbidity (CCI=0) 10610 (70.73) 
9388 (88.48) 1222 (11.52) <0.0001 
Chronic Obstructive 
Pulmonary Disease 
(COPD) 
1892 (12.61) 
1698 (89.75) 194 (10.25) 0.4072 
Diabetes 1300 (8.67) 1189 (91.46) 111 (8.54) 0.0058 
Cancer 640 (4.27) 600 (93.75) 40 (6.25) <0.0001 
Mild liver disease 442 (2.95) 405 (91.63) 37 (8.37) 0.0941 
Peripheral Vascular 
Disease (PVD) 405 (2.70) 
368 (90.86) 37 (9.14) 0.2722 
Cerebrovascular 
Disease (CVD) 346 (2.31) 
313 (90.46) 33 (9.54) 0.4417 
Diabetes sequelae 272 (1.81) 254 (93.38) 18 (6.62) 0.0247 
RA 239 (1.59) 219 (91.63) 20 (8.37) ns 
Congestive Heart 
Failure (CHF) 226 (1.51) 
213 (94.25) 13 (5.75) 0.0137 
Myocardial 
Infarction(MI) 178 (1.19) 
171 (96.07) 7 (3.93) 0.0030 
Renal disease 176 (1.17) 164 (93.18) 12 (6.82) 0.0865 
Metastatic cancer 70 (0.47) 70 (100) <=5 (≤7.14) <0.01 
Paralysis 51 (0.34) 46-50 (≤98.03) ≤5 (≤9.80) ns 
Ulcer 81 (0.54) 76-80 (≤98.77) ≤5 (≤6.17) ns 
Moderate to severe 
liver disease 31 (0.21) 
26-30 (≤96.77)  ≤5 (≤16.13) ns 
HIV/AIDS 32 (0.21) 25 (78.13) 7 (21.88) 0.0435 
CCI, mean, (SD) in 
12 months pre-index 0.540 (± 1.184) 
 
0.5571 (1.210) 
 
0.402 (0.936) 
 
<0.0001 
CCI, mean, (SD) 
during 1 year follow 
up period 
0.774 (± 1.480) 
 
0.780 (1.488) 
 
0.726 (1.407) 
 
0.1645 
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Table 1.3.  SCM Prescribing Rate by Diagnosing Practitioner Type, in Patients 
Diagnosed with Tobacco Dependence, LifeLink™ Health Plan Claims Database,   
July 2010-June 2011* 
*Multiple specialties diagnosing the patient on the same date possible    
GP=general practice, FP=family practice, NP=nurse practitioner, Ob/Gyn=obstetrics & gynecology, 
PA=physician’s assistant, ER=emergency room, pulm=pulmonogist, onc=oncologist, endo=endocrine, 
ENT=ear, nose & throat, gastro=gastroenterologist, ID=infectious disease, nephro=nephrologist, 
neuro=neurologist, ophth=ophthalmologist, optom=optometrist, phys med= physical medicine, 
pscych=psychiatrist, rheum=rheumatologist, urol=urologist, DM_HH=durable medical 
equipment/home health, PT=physical therapist, RN=registered nurse, SOC_WORK=social worker, 
MHSA_FAC=mental health/substance abuse facility                        
 Total (N=15,000) 
No Rx for SCM 
in 1 yr follow up 
(n=13,379) 
Rx for SCM in 1 
yr follow up 
(n=1,621) 
p-value 
General Medicine 
(GP/FP, Internal 
Medicine, NP, 
Ob/Gyn, Osteopath, 
PA) 
8543 (56.95) 
 
 
7317 (85.65) 
 
 
1226 (14.35) 
 
 
<0.0001 
Hospital related 
(surgical, ER, 
hospital?, 
anesthesia, 
Orthopedics) 
5285 (35.23) 
 
 
5025 (95.08) 
 
 
260 (4.92) 
 
 
<0.0001 
Specialist (e.g., 
cardiologist, 
pulm,onco, endo, 
ENT, 
gastro,ID,allergist, 
nephro, neuro, 
ophthl, optom,phys 
med, podiatrist, 
psychi,rheum,urol) 
1474 (9.83) 
 
 
 
1370 (92.94) 
 
 
 
104 (7.06) 
 
 
 
<0.0001 
Other (DME_HH, 
PT, RN, 
SOC_WORK, 
MHSA_FAC) 
318 (2.12) 
 
283 (88.99) 
 
35 (11.01) 
 
0.9077 
Pediatrics 
(pediatrics, neonatal) 95 (0.63) 
85 (89.47) 10 (10.53) 0.9296 
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Table 1.4.    Summary of Logistic Regression Analysis of Predictors of Treatment 
with SCM in Tobacco Dependent Patients: Odds Ratios and 95% Confidence 
Intervals  
Variable Odds Ratio 95% Wald CI 
Age <18 (ref=45-54) 0.353 0.084-1.479 
Age 18-24 (ref=45-54) 0.539 0.429-0.676 
Age 25-34 (ref=45-54) 1.135 0.962-1.338 
Age 35-44 (ref=45-54) 1.138 0.978-1.325 
Age 55-64 (ref=45-54) 1.066 0.782-1.452 
Age 56-75 (ref=45-54) 0.622 0.533-0.725 
Diagnosis by Pediatrician 
(ref=general medicine) 
0.880 0.447-1.735 
Diagnosis by Specialist 
(ref=general medicine) 
0.600 0.478-0.754 
Diagnosis by Hospital related 
Practitioner 
(ref=general medicine) 
0.332 0.285-0.386 
Diagnosis by Other (non-
physician)  
(ref=general medicine) 
0.840 0.543-1.302 
Pre-indexMI diagnosis 0.467 0.217-1.007 
Pre-index Cancer Diagnosis 0.701 0.503-0.978 
Pre-index HIV-AIDS 2.238 0.880-5.691 
Hosmer and Lemeshow Test p=0.7528 
ref=reference                                   
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Figure 1.1. Sample Selection.- Tobacco Dependent Patients and Treatment with 
SCM, LifeLink™ Health Plan Claims Database (July 2010-June 2011) 
 
LifeLink™ Health Plan Claims Database enrolled patients:  N=18,400,000 as of August 2012* 
 
Continuously enrolled patients January 2009 – June 2012  
Patients aged 16-76 identified as having any tobacco related diagnoses or procedure, SCM or smoking 
related cancers  
n = 117,695  
 
Patients identified as having any tobacco related diagnoses or procedures or smoking related cancers 
(Patient count without smoking cessation treatment)    
n=80,486  
 
Patients enrolled January 2009 to June 2012 with a diagnosis or procedure indicating tobacco 
dependence (Patient count without smoking related cancer) 
n=77,736 
 
 Patients with a diagnosis or procedure code indicating tobacco dependence between July 2010 
and June 2011 (index) 
n=18,619 
 
Patients with a diagnosis or procedure code indicating tobacco dependence between July 2010 and June 
2011 with claims activity throughout the study period (January 2009 – June 2012)  
n=16,417  
 
 Patients with no claims for SCM in the 18 month period pre-index 
n=15,000  
 
 No Rx claim for SCM in 12 months post 
index 
n = 13,379 
 
Rx claim for SCM in 12 months post-index 
n = 1,621 
*Closest estimate for continuously enrolled patients during the study period  is 18.4MM patients as of 
August 2012.  Enrollment is subject to change quarterly as updates are received from contributing 
health plans.  Largest changes are typically seen at year beginning when patients may leave a health 
plan and join another.  The data used for this study has been merged into a new larger database called 
Pharmetrics Plus which includes a larger number of contributing health plans.  The database that 
includes the data used for this study is archived and would require data restoration  to determine exact 
count. 
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Figure 1.2.  SCM Prescribed in 1 Year Following Diagnosis, LifeLink™ Health 
Plan Claims Database (July 2010-June 2011) (n=1647) 
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Background 
 
Duration of use of smoking cessation medications (SCM) has been associated 
with treatment success in clinical trials.1-3  However, literature reports of “real world” 
studies evaluating SCM treatment duration and quit outcome in clinical practice are 
few.  One United States (US) based population survey examined the association of 
duration of nicotine replacement therapy (NRT) use and found no/ association with 
quit rates, though the population surveyed was specific to Massachusetts, which 
provides free NRT to interested persons.4,5  In contrast,  results of a retrospective study 
employing Canadian survey data which examined the association between duration of 
NRT use and smoking cessation indicated that NRT use for less than 4 weeks was 
associated with reduced likelihood of cessation, whereas use for longer periods was 
associated with a higher likelihood of cessation.6  Of note, the aforementioned studies 
are limited to examination of NRT which is available over the counter (OTC) in the 
US and literature reports of US population-based studies examining the association of 
duration of prescription medication use with smoking cessation are scant.  However, 
one study employed the Tobacco Use Supplement to the US Current Population 
Survey and results indicated that treatment with SCM for at least 5 weeks was 
associated with higher likelihood of successful smoking cessation.7  No studies 
employing administrative claims data to assess duration of therapy (persistence) have 
been published.   
Another important consideration in assessing SCM use is recognition that tobacco 
dependence is a chronic disease that often requires repeated intervention with the 
 29 
 
average smoker making 6 to 9 lifetime quit attempts.8  Thus, patient relapse to tobacco 
use following a period of abstinence achieved with use of SCM is not unexpected.  
Treatment guidelines encourage clinicians to prescribe/recommend medications plus 
counseling for each quit attempt and research suggests that smokers are willing to 
make repeated pharmacotherapy assisted quit attempts.8,9  However, few reports exist 
in the literature that describe repeat therapy with SCM in clinical practice and none 
were found that use administrative data sources.   
In a single center retrospective cohort study of repeat treatment for smoking, Han, 
et al found that patients who relapsed to smoking and returned for repeat treatment 
exhibited signs of higher nicotine dependence and were more likely to have a history 
of treatment for mental health and other behavioral problems than patients who only 
attended for one treatment episode.10  Moreover, a randomized controlled trial (RCT) 
evaluating intensive disease management strategies for smokers over time found that 
smokers are willing to make repeated quit attempts using SCM, leading to 
progressively greater smoking abstinence.9  Study of repeat treatment in a large  
national population could identify patient or provider characteristics associated with 
repeat treatment and inform specific approaches to management in patient subgroups.  
The objectives of this study were to describe treatment persistence in newly diagnosed 
tobacco dependent patients prescribed SCM in the 1 year following diagnosis, repeat 
treatment with SCM and patient and prescriber characteristics associated with 
premature discontinuation and repeat therapy. 
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Methods 
Design: This study employed a retrospective cohort design using de-identified 
data from the LifeLink™ Health Plan Claims Database (formerly known as 
Pharmetrics) which is comprised of commercial health plan information obtained from 
managed care plans throughout the US.  It is fully adjudicated medical and 
pharmaceutical claims for over 68 million unique patients from over 102 health plans 
across the U.S. (approximately 16 million covered lives per year).  The database 
includes both inpatient and outpatient diagnoses (In International Classification of 
Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] format) and procedures 
(in Current Procedure Terminology [CPT-4] codes and Healthcare Common 
Procedure Coding System [HCPCS] formats) as well as both retail and mail order 
prescription records.  Available data on prescription records include the National Drug 
Code (NDC) as well as the quantity of the medication dispensed.  Charge, allowed and 
paid amounts are available for all services rendered, as well as dates of service for all 
claims.  Additional data elements include demographic variables (age, gender, 
geographic region), product type (e.g., HMO, PPO), payer type (e.g., commercial, 
self-pay), provider specialty, and start and stop dates of health-plan enrollment. 
Sample Selection: The sample consisted of patients aged 16-76 newly identified 
as tobacco dependent through presence of a diagnosis code for tobacco use disorder 
and/or CPT code for tobacco cessation counseling, advice or treatment (Appendix) 
during the period July 2010 to June 2011 (index). Patients with ICD-9, CPT codes, or 
prescriptions related to tobacco dependence or treatment in the lookback period 
January 2009 through June 2010 were excluded.  Charlson Comorbidity Index (CCI) 
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scores for each patient were calculated using the algorithm develop by Quan, et al., 
through identification of ICD-9 codes related to 17 co-morbidity categories in the 
12 month period prior to (pre-index)  and 12 month period following the index date 
(including the index date).  Weights specific to each co-morbidity category were 
assigned and the CCI score calculated; higher CCI scores indicate greater co-
morbidity.11    
Statistical Analysis:  Descriptive statistics were used to describe demographic and 
clinical characteristics and frequency of prescription of SCM defined as 1 or more 
claim for varenicline, bupropion SR or NRT during the 1 year period following 
tobacco dependence diagnosis or CPT code or procedure.  Demographic 
characteristics included patient age at index, gender, geographic region of residence 
and insurance related factors such as payer type and insurance product.  Clinical 
characteristics included baseline 12 month pre-index CCI score and CCI categories.  
Provider characteristics included the practitioner type associated with diagnosis of or 
counseling/advice for tobacco dependence. 
Two dichotomous response variables were defined:  Premature discontinuation 
and repeat therapy.  Premature discontinuation or non-persistence was defined as 
duration of therapy less than 12 weeks (84 days) based on recommended duration of 
therapy as described in FDA approved product information for varenicline and 
bupropion SR and, due to multiple available formulations, expert recommendation for 
NRT.12-14  Data fields employed to calculate duration of therapy included the patient 
identification number, product name, prescription fill date and days supply.  Time to 
discontinuation in days was measured using a refill grace period equal to one-half the 
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days supplied of the previous prescription. Repeat treatment was defined based on 
criteria used by Han, et al.10  Patients were identified as having repeat therapy if a span 
of ≥ 26 week was observed between any 2 consecutive treatment episodes in the 1 
year following initiation of SCM.  Bivariate analyses including t-tests for continuous 
variables and chi-square tests or Fisher’s Exact test for categorical variables were used 
to analyze differences in patient and provider characteristics.   
Assessment of factors associated with premature discontinuation or repeat therapy 
was performed by conducting a series of univariate logistic regression equations. To 
qualify for multivariate logistic regression, variables had to be associated with SCM 
prescription in the univariate analyses (p<0.2) or be otherwise clinically important.  
Two multivariate logistic regression models were constructed; the first assessed 
relationships between the independent variables (IVs) of patient and provider 
characteristics and the dependent variable (DV) of premature discontinuation of SCM 
therapy and the second assessed relationships between the IVs of patient and provider 
characteristics and the dependent variable (DV) of repeat SCM therapy as defined 
using Han’s criteria.  For modeling the DV of repeat therapy, infrequently occurring 
(≤5 patients) independent variable categories were combined. Each model was created 
using a backward elimination process and the likelihood ratio test and AIC used to 
assess the model at each step, removing least statistically significant covariates with 
each iteration and evaluating differences between full and reduced models for 
statistical significance.  In advance of model inclusion, parametric form of any 
continuous independent variables and multicollinearity among independent variables 
were assessed.  Multicollinearity was assessed by regressing independent variables 
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against the independent variable of patient age at index.  Main effects and two factor 
interactions of independent variables found significant in the models were assessed. 
The Hosmer-Lemeshow test was used to assess goodness of fit of the final models.  
The measure of effect is presented as an odds ratio with corresponding 95% 
confidence intervals. All analyses were conducted using SAS® Version 9.4 (SAS 
Institute, Cary, NC) with statistical significance defined as p <0.05.  Analyses were 
performed using a 2-tailed alpha of 0.05 and 95% confidence intervals calculated.  
 
Results 
Cohort 
In total, 1621 of 15,000 (10.81%) newly diagnosed tobacco dependent patients 
initiated therapy with SCM in the 1 year following diagnosis (Figure 1).  Of treated 
patients, mean (SD) age was 44.56 (12.52) years, 57.13% were female and most 
(82.11%) resided in the Midwest.  Mean (SD) pre-index Charlson Comorbidity index 
score (CCI) was 0.402 (0.935) and most (86.12%) had commercial insurance and an 
HMO insurance product (69.77%).  Most (75.63%) were diagnosed by a general 
medicine practitioner (Table 1).  Smoking cessation medication prescriptions in the 1 
year post-index included 71 (4.38%) bupropion SR, 450 (27.76%) NRT and 1126 
(69.46%) varenicline (Figure 2).  
Persistence 
Mean (SD) duration of therapy in all treated patients was 36.35 (25.74) days. 
Premature discontinuation, defined as duration of therapy <84 days, was observed in 
1506 (92.91%) of patients.  Mean (SD) age of patients who prematurely discontinued 
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SCM was 44.29 (12.55) years and mean (SD) pre-index baseline CCI was 0.4070 
(0.9497). Differences were observed by age group with patients >50 years being less 
likely to discontinue prematurely than their younger counterparts (p=0.0040), and also 
by region (p=0.0052) with the highest rates in patients from the East (94.25%) and 
lowest in patients from the South (≤5) and West (84.55%)  Premature discontinuation 
did not differ according to CCI score category (p=0.4778) with the highest rate in 
patients with CCI=1 (94.64%) and lowest in CCI ≥2 (92.03%) (Tables 1, 2).  Overall, 
premature discontinuation was similar (p=0.0705) by payer type and insurance 
product with highest and lowest rates in patients with Medicaid (94.96%) and 
Medicare Supplemental (83.33%) and POS (93.71%) and PPO (88.42%), respectively.  
Premature discontinuation was not different (p=0.7875) by diagnosing provider type 
with highest reportable (count >5) rate in patients diagnosed by hospital related 
practitioners (93.85%) (Table 3).  No difference in premature discontinuation rate was 
observed between in patients who ultimately repeated therapy and those who did not 
(p=0.8291) (Table 3).  Differences were observed in rates of premature 
discontinuation between SCM with the highest rate in nicotine policrilex (97.47%) and 
lowest in bupropion SR (80.28%)  (p<0.001) (Table 1). 
Multivariate logistic regression analysis revealed that patients in age groups 51-
64 years had slightly lower likelihood of premature discontinuation compared to 
patients age 41-50 (OR 0.584, 95% CI 0.354-0.962), as did patients residing in the 
South or West compared to those residing in the Midwest (OR 0.325, 95% CI 0.173-
0.610) .  Patients in Medicaid had higher likelihood of premature discontinuation 
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compared to those with commercial insurance (OR 2.898, 95% CI 1.179-7.122) (Table 
5). 
Repeat Therapy 
Of the 1621 treated patients, 86 (5.3%) were identified as having repeat therapy 
and mean (SD) age in this group was 44.3 (12.88) years and pre-index baseline mean 
(SD) CCI score in patients who repeated therapy was 0.4186 (1.034).  Repeat 
treatment rate was similar in females and males (5.62% vs 4.89%, p=0.5201).  Patients 
in CCI score category ≥2 had the lowest rate of repeat therapy (4.35%, p=0.8379).  
Rates of repeat therapy by insurance product (p=0.3084), payer type (p=0.7956) and 
diagnosing practitioner type (p=0.2773) were similar with the lowest rates in patients 
with consumer directed insurance (≤5) and indemnity (≤5) and highest in patients with 
HMO (6.02%). Repeat treatment rate by age group was similar (p=0.4242) and lowest 
in the youngest and oldest age groups of 17-19 (≤5) and 65-75 (≤5) with patients 20-
49 years having the highest repeat therapy rate (5.95%).  Similarly, no difference was 
observed in repeat treatment by region with lowest counts in patients residing in the 
South and West (≤5) and highest in the East (5.75%).  No difference in premature 
discontinuation rates (5.39% vs. 94.62%, p=0.6346) or mean (SD) duration of initial 
therapy (34.53 [20.14] days vs. 36.43 [26.02] days, p=0.5071) was observed in 
patients who repeated therapy compared to those who did not.  Repeat therapy rates 
did not differ among products (p=0.919) (Table 5).  Multivariate regression analysis 
revealed no variables that were associated with repeat therapy (Table 7). 
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Discussion 
Population assessments of persistence with SCM are few and are derived largely 
from survey data with some focusing exclusively on NRT.4,6,7,15  Though study design, 
data source and populations differ, our findings related to premature discontinuation 
can be compared most closely to a study of international survey data that used a 
threshold to define premature discontinuation. The authors defined premature 
discontinuation as self-report of <8 weeks of treatment, whether OTC or prescription, 
and found that most patients studied (69%) discontinued therapy prematurely.15  These 
authors concluded that older age was a significant predictor of completing >8 weeks 
of therapy (OR 1.02, 95% CI 1.01-1.03) and that completion of a full 8 weeks of SCM 
was more likely among prescription SCM users (OR 1.82, 95% CI 1.29 – 2.57) and 
females (OR 1.16, 95% CI 0.88-1.53), though the confidence interval for the latter 
included 1.0.  Of prescription SCM users in that study, duration of therapy 8 weeks or 
more was reported by 40.4%.  
In the present study using administrative claims data which are exclusive to 
therapies dispensed by prescription, results indicate that >90% of newly diagnosed 
tobacco dependent patients discontinue therapy before 12 weeks. We found that 100% 
of patients <20 years old discontinued prematurely and those between 51 and 64 years 
were slightly less likely to premature discontinuation compared to those aged 41-50 
(OR 0.584, 95% CI 0.354 – 0.962). We found no difference (p=0.2657) in the rate of 
premature discontinuation between males and females and no association of gender 
with premature discontinuation.  Mean duration of therapy in the current study was 
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approximately 36 days and only 15% had duration of therapy >8 weeks (Data not 
shown).  
We did observe regional differences (p= 0.0052) in premature discontinuation 
rate with the lowest rate in the West (84.55%) but comparisons were hampered by low 
counts of treated patients from the South.  Residence in the West or South was 
associated with slightly lower likelihood of premature discontinuation (OR 0.354, 
95% CI 0.354-0.962) compared to the Midwest, however these results are likely 
influenced by the lower premature discontinuation rate in the West because of low 
SCM utilization in the South (≤5 patients treated; ≤5 prematurely discontinuing).  
Literature reporting SCM persistence in different US regions has not been found.  
Patients with Medicaid had higher likelihood of premature discontinuation compared 
to those with commercial insurance (OR 2.898, 95% CI 1.179-7.122), though the 
confidence interval is wide.  Similar to aforementioned lack of information regarding 
reports of SCM persistence rates by region, reports of persistence with SCM by payer 
type have not been found.    
Differences were observed in rates of premature discontinuation between SCM 
with highest rate in nicotine polacrilex (97.47%) and lowest in bupropion SR 
(80.28%) (p<0.001).  As mentioned previously, population based studies reporting 
SCM persistence is scant but, in a randomized controlled trial (RCT) comparing the 
efficacy and safety of varenicline and bupropion SR, discontinuation rates in those 
receiving treatment were similar with 24.12% varenicline and 29.14% of bupropion 
SR subjects discontinuing therapy; 10.5% due to adverse events in the varenicline 
group, and 12.6% in the bupropion SR group.16  Similar results were observed in a 
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parallel RCT of varenicline and bupropion.17  Differences in mechanisms of action of 
these two drugs could yield different responses, such as reduction in craving, nicotine 
withdrawal symptoms and rewarding effects of smoking.18    Bupropion SR is 
indicated in both depression and as a smoking deterrent so use in patients with mental 
health diagnoses was possible.   
Of note, in their survey of smokers or recent ex-smokers having used SCM in a 
quit attempt in the previous year, Balmford, et al15 found that the most commonly 
reported reason for discontinuation was relapse/medication didn’t work (41.6%).  
Interestingly, this reason was much less commonly reported among users of 
prescription only medication; discontinuation was described more frequently as related 
to side effects.  The authors found no difference in proportions of patients completing 
treatment courses of oral NRT and the patch.15  Of note, a considerable portion of 
SCM users (17%) in this study believed they no longer needed to use medication, and 
two thirds of those who believed the medication had worked achieved 6 months 
continuous abstinence.11  The authors note that people may be able to judge the 
appropriate time to discontinue medication and suggest that a trial of participant point 
of discontinuation may be worthwhile. 
Tobacco dependence is a chronic disease that often requires repeated intervention 
and multiple attempts to quit but few reports exist that describe repeat therapy with 
SCM in actual practice.  In a single center retrospective cohort study, Han, et al 
studied the characteristics of patients who relapsed to smoking and returned to the 
clinic for repeat treatment.10  The authors defined a repeat patient as one who attended 
clinic for two or more treatment episodes during the study period with each episode 
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being separated by at least 26 weeks.  The study results indicated that 14.4% of 
patients repeated treatment which was more common between ages 25 and 64 than 
younger or older age groups (p=0.017) and in patients who had private insurance 
(56.6%, p=0.010).  In the current study, repeat treatment was observed in ~5% of 
newly diagnosed tobacco dependent patients initiating SCM and demographic and 
clinical characteristics, insurance related factors, and diagnosing practitioner types in 
those repeating treatment were similar to those who did not.   It is possible that those 
patients for whom providers use diagnosis codes for tobacco cessation or counsel for 
tobacco cessation are those with high levels of tobacco dependence and these patients 
have been found to have greater rates of smoking relapse following a quit attempt.19  
While not a study of routine practice, results of a randomized controlled trial of 
community based patients participating in a longitudinal intensive smoking cessation 
management program indicated that, by study end, 23%, 33% , 23%, 12% and 9% 
requested a total of 0,1,2,3 or 4 cycles of pharmacotherapy, respectively.9 
This study utilized data from medical and pharmacy claims which are collected 
for billing and reimbursement purposes and which have inherent limitations.  Data 
entry errors at sites of care cannot be detected or corrected in data analysis. We used 
ICD-9-CM and tobacco cessation counseling specific CPT and HCPCS codes to 
identify newly diagnosed smokers.   This method may under-estimate the number of 
smokers, however use of ICD-9-CM codes to identify smokers has been validated 
previously.20 The use of prescription claims exclusively in the current study may have 
missed the use of over the counter (OTC) products, but in an US insured population, 
over the counter SCM may be covered under the pharmacy benefit.  The small number 
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of patients in some subgroups evaluated precludes comparisons by statistical analysis 
and thus, results are descriptive in nature.  It is important to note that though patients 
were identified as smokers through diagnosis or procedure codes, this provides no 
insight into readiness to quit which is an important component of cessation attempts.8  
Also, as mentioned only prescription SCM could be captured and payment of a 
prescription claim does not mean that a patient used the medication as prescribed and 
does not represent those prescriptions that may have been written but not filled by the 
patient.  Thus, treatment rates may be underestimated in this sample. 
Identification of SCM use or tobacco dependence diagnosis or procedure prior to 
the lookback period was not possible, thus patients may have been misclassified as 
newly diagnosed and/or newly treated with SCM.  In addition we did not identify any 
mental health comorbidities in which bupropion SR could have been used to treat both 
conditions.   
Recommended duration of therapy for specific SCM can vary based on level of 
tobacco dependence and clinical information such as level of tobacco dependence is 
not ascertainable in claims data.  The threshold of 12 weeks was chosen as it is the 
minimum recommendation for varenicline, upper limit of recommendation for 
bupropion SR and within recommendations for NRT.12-14  Premature discontinuation 
of SCM does not mean that patients did not quit.  Aforementioned population studies 
found that patients successfully quit using shorter than recommended durations of 
therapy, however cessation rates have been found to be highest among those who use 
prescription medication for ≥5 weeks.6,7 
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Future research using administrative claims data should focus on different 
persistence thresholds and include longer study periods.  Additionally, long term 
prospective study of patients using SCM would facilitate study of persistence and 
repeat therapy.  Important clinical information could be gained by linking 
administrative claims to electronic medical record data in a HIPAA compliant fashion. 
Despite stated limitations, this study adds useful information regarding 
persistence and repeat use of prescription SCM in a US  national population.  
Specifically, mean persistence with SCM was approximately 36 days and >90% of 
patients discontinued SCM before 12 weeks of therapy; shorter than 
recommendations.  Patients under 50 years and 65 or older were more likely to 
discontinue prematurely than patients 50-58 years old.  Few patients (5%) repeated 
therapy and, in this study with small sample size, no patient or provider characteristics 
were associated with repeat therapy. 
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Table 2.1. Demographic Characteristics of Tobacco Dependent Patients with 
Premature SCM Discontinuation , LifeLink™ Health Plan Claims Database   
(July 2010-June 2011)                                                   
PPO = Preferred Provider Organization, POS = Point of Service 
  Total   
(N = 1621) 
Premature 
Discontinuation 
= no (n=115) 
Premature 
 Discontinuation = 
yes (n=1506) 
 
p-value 
Age at index, years, mean, 
(SD)  
44.56 
(12.52) 48.15 (11.59) 44.29 (12.55) 
0.0014 
Age Category, No. (%) 
17-19 30 (1.85) 0 30 (100)  
 
 
0.0040 
20-49 958 (59.06) 52 (45.22) 906 (94.57) 
50-58 (reference) 419 (25.83) 45 (39.13) 374 (89.26) 
59-64 150 (9.25) 12 (10.43) 138 (92.0) 
65-75 65 (4.01) 6 (5.22) 59 (90.77) 
Gender, No. (%) 
Female 926 (57.13) 60 (6.47) 866  (93.53) 
 
0.2657 
Male 695 (42.75) 55 (7.91) 640  (92.09) 
Region, No. (%) 
East 174 (10.73) 10  (5.75) 164 (94.25) 
 
 
 
<0.01 Midwest 
1336 
(82.11) 88 (6.58) 1248 (93.41) 
South ≤5 (≤0.31) 0 ≤5 (≤100) 
West (reference) 110 (6.79) 17 (15.45) 93 (84.55) 
Insurance Related, No. (%) 
Product Type Consumer 
Directed 68 (4.19) ≤5 (≤7.35) 63 (93.65) 
 
 
 
 
ns 
Product Type HMO 
(reference)   
1131 
(69.77) 81 (7.16) 1049 (92.84) 
Product Type Indemnity   20 (1.23) ≤5 (≤25.0) 18 (≤95.0) 
Product Type POS   795 (49.04) 50 (6.30) 745 (93.70) 
Product Type PPO   95 (5.86) 11 (11.58) 84 (88.42) 
   
Payer Type Commercial 
(reference) 
1396 
(86.12) 103 (7.37) 1293 (92.62) 
 
 
 
ns 
Payer Type Medicaid   
258 
(15.91) 13 (5.04) 245 (94.96) 
Payer Type Medicare    57 (3.52)  9 (15.79)  48 (84.21) 
Payer Type  Self-insured   130 (8.02) 9 (6.92) 121 (93.08) 
Pharmacy Benefit 
1544 
(95.25) 107 (6.93) 1438 (93.07) 
0.2485 
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Table 2.2. Clinical Characteristics of Tobacco Dependent Patients with 
Premature SCM Treatment Discontinuation, LifeLink™ Health Plan Claims 
Database   (July 2010-June 2011)*                                                 
*Results presented only for Charlson Comorbidities cell counts >5 
 
 
  Total   
(N = 1621)
Premature 
Discontinu-
ation = no 
(n=115)
Premature 
 Discontinuation = yes 
(n=1506)
 
p-value 
Pre-index Charlson 
Comorbidity Index 
(CCI), mean, (SD) 
0.402 
(0.935) 
0.3391 
(0.7241) 0.4070 (0.9497) 
 
0.4532 
Pre-index CCI 0, n 
(%) (Reference) 1223 (75.44) 90 (7.36) 1133 (92.64) 
 
 
0.4778 Pre-index CCI  1, n 
(%) 261 (16.10) 14 (5.36) 247 (94.64) 
Pre-index CCI  ≥2, n 
(%) 138 (8.51) 11 (7.97) 127 (92.03) 
Chronic Obstructive 
Pulmonary Disease 
(COPD) 
194 (11.97) 17 (8.76) 177  (91.24) 
 
0.3347 
Mean (SD) Duration 
of Therapy (days) 
36.35 
(25.74)   
 
Repeat Treatment 86 (5.30) ≤5 (≤5.81) ≤85 (≤98.84) ns 
Bupropion SR 
(n=71), No. (%)  14 (19.72) 
57 (80.28)  
 
<0.0001 
Nicotine  (n=371),  
No. (%)  8 (2.16) 
363 (97.84) 
Nicotine Polacrilex 
(n=79),  No. (%)  ≤5 (≤6.33) 
≤78 (≤98.73) 
Varenicline (n=1126), 
No. (%)  92 (8.17) 
1034 (91.83) 
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Table 2.3.  Characteristics of Diagnosing Practitioners for Tobacco Dependent 
Patients with Premature SCM Treatment Discontinuation, LifeLink™ Health 
Plan Claims Database  (July 2010-June 2011)                                                   
 
GP=general practice, FP=family practice, NP=nurse practitioner, Ob/Gyn=obstetrics & gynecology, 
PA=physician’s assistant, ER=emergency room, pulm=pulmonogist, onc=oncologist, endo=endocrine, 
ENT=ear, nose & throat, gastro=gastroenterologist, ID=infectious disease, nephro=nephrologist, 
neuro=neurologist, ophth=ophthalmologist, optom=optometrist, phys med= physical medicine, 
pscych=psychiatrist, rheum=rheumatologist, urol=urologist, DM_HH=durable medical 
 
 Total   
(N = 1621)
Premature 
Discontinu-
ation = no 
(n=115)
Premature 
 Discontinuation = yes 
(n=1506)
 
p-value 
General Medicine 
(GP/FP, Internal Med, 
NP, Ob/Gyn, 
Osteopath, PA) 
1226 (75.63) 90 (7.34) 1136 (92.66) 
 
 
 
 
 
 
 
 
 
ns 
Hospital related 
(surgical, ER, 
hospital, anesthesia, 
Ortho) 
260 (16.04) 16 (6.15) 244 (93.85) 
Specialist (e.g., 
cardiologist, 
pulmonol,oncol, 
endocrine, ent, 
gastro,ID,allergy, 
nephrol, neurol, 
ophthal, optom,phys 
med, podiatry, 
psychiatry,rheum,urol
) 
104 (6.42) 9 (8.65) 95 (91.35) 
Other (DME_HH, PT, 
RN, SOC_WORK, 
MHSA_FAC) 
35 (2.16) ≤5 (≤14.28) 
≤34 ≤97.14) 
Pediatrics (pediatrics, 
neonatal) 10 (0.62) ≤5 (≤50.0) ≤9 (≤90.0) 
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Table 2.4. Demographic Characteristics of SCM Treated Patients with Repeat 
Therapy LifeLink™ Health Plan Claims Database  (July 2010-June 2011)            
Repeat therapy defined if a span of ≥ 26 week was observed between any 2 consecutive treatment 
episodes in the 1 year following initiation of SCM.  PPO = Preferred Provider Organization, POS = 
Point of Service 
  Total   
(N = 1621) 
No repeat ≥26 
weeks 
(n=1535) 
Repeat Rx ≥26 
weeks (n=86) 
p-value 
Age at index, years, 
mean, (SD)  44.56 (12.52) 
44.57 (12.51) 44.30 (12.88) 0.8431 
Age Category, No. (%)** 
17-19 30 (1.85) 29 (96.67) ≤5 (≤16.67)  
 
 
ns 
20-49 958 (59.06) 900 (94.04) 57 (5.95) 
50-58 (reference) 419 (25.83) 403 (96.18) 16 (3.82) 
59-64 150 (9.25) 143 (95.33) 7 (4.67) 
65-75  65 (4.01) ≤64 (≤98.46) ≤5 (≤7.69) 
Gender, No. (%) 
Female 926 (57.13) 874 (94.398 52 (5.62)  
0.5201 Male 695 (42.75) 661 (95.11) 34 (4.89) 
Region, No. (%) 
East 174 (10.73) 164 (94.25) 10 (5.75)  
ns Midwest 1336 (82.11) 1262 (94.46) 74 (5.54) 
South ≤5 (≤0.31)  ≤5 (≤0.31) 0 
West 
(reference)*** 110 (6.78) 
108 (98.18) ≤5 (≤4.55) 
Insurance Related, No. (%) 
Consumer Directed 68 (4.19) 
 
≤67 (≤98.53) 
 
≤5 (≤7.35) 
 
 
 
 
ns 
Insurance Product 
HMO 
(reference)****   
1131 (69.77) 
 
1062 (93.98) 
 
68 (6.02) 
Indemnity   20 (1.23) ≤19 (≤95.0) ≤5 ≤25) 
Insurance Product 
POS   795 (49.01) 
752 (94.71) 42 (5.29) 
Insurance Product 
PPO   95 (5.86) 
≤94 (≤98.95) ≤5 (≤5.26) 
   
Payer Type 
Commercial 
(reference)† 
1396 (86.12) 
 
1320 (94.56) 
 
76 (5.44) 
 
 
 
 
ns Payer Type 
Medicaid   258 (15.91) 
244 (94.57) 14 (5.43) 
Payer Type 
Medicare 57 (3.53) 
≤56 (≤98.25) ≤5 (≤8.77) 
Payer Type Self-
insured   130 (8.02) 
124 (95.38) 6 (4.62) 
Pharmacy Benefit 1544 (95.25) 1459 (94.49) 85 (5.51) 0.1221 
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Table 2.5.  Rate of Repeat Therapy by Clinical Characteristics and Diagnosing 
Practitioner Type in Patients Treated with SCM,  LifeLink™ Health Plan Claims 
Database  (July 2010-June 2011) 
*Results presented only for Charlson Comorbidities with cell counts >5;  GP=general practice, 
FP=family practice, NP=nurse practitioner, Ob/Gyn=obstetrics & gynecology, PA=physician’s 
assistant, ER=emergency room, pulm=pulmonogist, onc=oncologist, endo=endocrine, ENT=ear, nose 
& throat, gastro=gastroenterologist, ID=infectious disease, nephro=nephrologist, neuro=neurologist, 
ophth=ophthalmologist, optom=optometrist, phys med= physical medicine, pscych=psychiatrist, 
rheum=rheumatologist, urol=urologist, DM_HH=durable medical equipment/home health, PT=physical 
therapist, RN=registered nurse, SOC_WORK=social worker, MHSA_FAC=mental health/substance 
abuse facility 
  Total   (N = 1621) 
No repeat ≥26 
weeks (n=1535) 
Repeat Rx ≥26 weeks 
(n=86) 
p-
value 
Pre-index Charlson Comorbidity 
Index, mean, (SD)  0.402 (0.935) 
 0.4013 (0.9300) 0.4186 (1.034) 0.8675 
Pre-index CCI 0, n (%) 
(Reference) 1223 (75.44) 
1157 (94.68) 65 (5.32)  
 
0.8379 Pre-index CCI  1, n (%) 261 (16.10) 246 (94.25) 15 (5.75) 
Pre-index CCI  ≥2, n (%) 138 (8.51) 132 (95.65) 6 (4.35) 
Chronic obstructive pulmonary 
disease  194 (11.97) 
183 (94.33) 11 (5.67) 0.8091 
Diagnosing Practitioner Type, No (%) 
General Medicine (GP/FP, 
Internal Med, NP, Ob/Gyn, 
Osteopath, PA) 
1226 (75.563) 
 
1159 (94.54) 
 
67 (5.46) 
 
 
 
 
 
ns 
Hospital related (surgical, ER, 
hospital, anesthesia, Ortho) 260 (16.04) 
253 (97.31) 7 (2.69) 
Specialist (e.g., cardiologist, 
pulm,onc, endo, ent, 
gastro,ID,allergist, nephro, neuro, 
ophth, optom,phys med, 
podiatrist, psych,rheum,urol) 
105 (6.42) 
 
 
97 (93.27) 
 
 
7 (6.73) 
Other (DME_HH, PT, RN, 
SOC_WORK, MHSA_FAC) 35 (2.16) 
 
≤34 (≤97.14) 
  
≤5 (≤14.29) 
Treatment Patterns 
Premature discontinuation 
(duration of therapy <84 days) 
No. (%) 
1506 (92.91) 
1425 (94.62) 81 (5.39)  
0.6346 
Duration of Therapy,  mean (SD) 1621 (100) 36.43 (26.02) 34.53 (20.14) 0.5071 
Bupropion SR (n=71)  67 (94.37) ≤5 (≤98.59)  
 
ns Nicotine  (n=371)  355 (95.69) 16 (4.31) 
Nicotine Policrilex (n=79)  76 (96.20) ≤5 (≤98.73) 
Varenicline (n=1126)  1071 (95.03) 56 (4.97) 
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Table 2.6.  Summary of Logistic Regression Analysis of Predictors of Premature 
Discontinuation of SCM: Odds Ratios and 95% Confidence Intervals  
Independent Variable  OR 95% Wald CI 
Age < 28 years 
(ref=41-50 years) 
3.164 0.939-10.662 
Age 28-40 
 (ref=41-50 years) 
0.946 0.535-1.676 
Age 51-64 years 
(ref=41-50) 
0.584 0.354-0.962 
 Age 65-75 years 
(ref=41-50 years) 
0.796 0.292-2.171 
East Region  
(ref=Midwest) 
1.478 0.726-3.012 
South & West Regions 
(ref=Midwest) 
0.325 0.173-0.610 
Medicare and Self Insured 
(ref=commercial) 
1.151 0.384-3.446 
Medicaid (ref=commercial) 2.898 1.179-7.122 
Hosmer-Lemeshow Goodness of Fit Test       p=0.8672 
ref=reference 
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Table 2.7.   Summary of Logistic Regression Analysis of Predictors of Repeat 
SCM Therapy:  Odds Ratios and 95% Confidence Intervals  
Independent Variable  OR 95% Wald CI 
Indemnity (ref=HMO) 0.329 0.045-2.424 
POS (ref=HMO) 0.623 0.355-1.093 
Diagnosis by non-physician or pediatrician or 
specialist (ref=general medicine) 
1.176 0.550-2.513 
Diagnosis by hospital related practitioner 
(ref=general medicine) 
0.464 0.198-1.087 
Hosmer-Lemeshow Goodness of Fit Test                  p=0.9775 
ref=reference; HMO=health maintenance organization, POS=Point of Service 
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Figure 2.1. Sample Selection – Tobacco Dependent Patients Treated with SCM 
and Repeat Therapy, LifeLink Health Plan Claims Database (July 2010-June 
2011) 
PharMetrics enrolled patients:  N=18,400,000 as of August 2012* 
 
Continuously enrolled patients January 2009 – June 2012  
Patients aged 16-76 identified as having any tobacco related diagnoses or procedure, SCM or smoking 
related cancers  
n = 117,695  
 
Patients identified as having any tobacco related diagnoses or procedures or smoking related cancers 
(Patient count without smoking cessation treatment)    
n=80,486  
 
Patients enrolled January 2009 to June 2012 with a diagnosis or procedure indicating tobacco 
dependence (Patient count without smoking related cancer) 
n=77,736 
 
 Patients with a diagnosis or procedure code indicating tobacco dependence between July 2010 
and June 2011 (index) 
n=18,619 
 
Patients with a diagnosis or procedure code indicating tobacco dependence between July 2010 and June 
2011 with claims activity throughout the study period (January 2009 – June 2012)  
n=16,417  
 
 Patients with no claims for SCM in the 18 month period pre-index 
n=15,000  
 
Rx claim for SCM in 12 months post-index 
n = 1,621 
 
Repeat Rx ≥ 26 weeks  
n=86 
*Closest estimate for continuously enrolled in Pharmetrics during the study period  is 18.4MM patients 
as of August 2012.  Enrollment is subject to change quarterly as updates are received from contributing 
health plans.  Largest changes are typically seen at year beginning when patients may leave a health 
plan and join another.  The Pharmetrics data used for this study no longer exists in this form as IMS has 
created a new larger database called Pharmetrics Plus which includes a larger number of contributing 
health plans.  The database that includes the data used for this study is archived offsite and would 
require data restoration  to determine exact count. 
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Figure 2.2.  SCM Prescribed in 1 Year Following Diagnosis of Tobacco 
Dependence, LifeLink Health Plan Claims Database (July 2010-June 2011) 
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Background 
Smoking increases the risk of numerous cancers, and continued smoking by 
cancer patients and cancer survivors has been shown to have detrimental effects on 
health.  In a recent meta-analysis, Parsons et al reported that continued smoking was 
associated with an increased risk of mortality, disease recurrence and development of 
a second primary tumor in lung cancer patients.1    Moreover, continued smoking can 
alter the pharmacokinetics of chemotherapeutic drugs, leading to lower serum 
concentrations of the drug which may alter its therapeutic effect.2   In 2006, the 
American Society for Clinical Oncology (ASCO) introduced the Quality Oncology 
Practice Initiative (QOPI), which has become a key component of a measurement 
system to promote quality cancer care.   Quality measures include those related to 
smoking cessation (SC) such as documentation of smoking status/tobacco in the past 
year, smoking/tobacco use cessation counseling recommended to smokers/tobacco 
users in the past year, and smoking/tobacco use cessation administered appropriately 
in the past year.3 It’s important to note that patients with cancer who try to quit 
smoking often do so without formal assistance which typically yields low success 
rates.4   
Further evidence of the need to foster SC in cancer patients is the issuance by the 
National Comprehensive Cancer Network (NCCN) of clinical practice guidelines 
focused on smoking cessation recommendations for patients with cancer.  These 
guidelines recommend that treatment plans for all smokers with cancer include 
evidence based pharmacotherapy, behavior therapy and close follow-up with 
retreatment as needed.5  However, information regarding the extent of employment of 
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SC interventions, including SC medications (SCM), in cancer patients is lacking. Of 
note, results of a survey by Warren et al report that physicians caring for lung cancer 
patients believe that current smoking affects outcomes and that tobacco cessation is a 
necessary part of clinical care, but few provide assistance to their patients as a routine 
part of cancer care.6 
Health-related databases, including claims databases, are an important data source 
for research.  One strength of these data is that they allow researchers to examine 
medical care utilization as it occurs in routine clinical care or the “real world”. These 
data sources can provide large study populations, long observation periods and allow 
for examination of specific sub-populations.7  Though they are not without limitations, 
adequately controlled observational studies using administrative claims data can 
answer important questions in a relatively inexpensive and time-efficient manner.7    
The utility of the LifeLink® database in studying SC interventions in patients with 
smoking related co-morbidities was demonstrated by Make, et al in their study of 
COPD in which they found that 82% of patients reported to be current smokers and 
90% of current smokers in the Medicare population did not receive smoking cessation 
interventions  within 45 days of hospitalization for exacerbation of COPD.8   
The study of SC treatment in patients with smoking related cancers in a  national  
population could identify potential gaps in quality care.  The objective of this study 
was to describe the epidemiology of SCM prescribing in newly identified tobacco 
dependent patients with smoking related cancers and patient or provider characteristics 
associated with its use.   
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Methods 
Design:  This study employed a retrospective cross-sectional design using  de-
identified data  from the LifeLink™ Health Plan Claims Database (formerly known as 
Pharmetrics) which is comprised of commercial health plan information obtained from 
managed care plans throughout the US.  The database contains fully adjudicated 
medical and pharmaceutical claims for over 68 million unique patients from over 102 
health plans across the U.S. (approximately 16 million covered lives per year).  The 
database includes both inpatient and outpatient diagnoses (In International 
Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] format) 
and procedures (in Current Procedure Terminology [CPT-4] codes and Healthcare 
Common Procedure Coding System [HCPCS] formats) as well as both retail and mail 
order prescription records.  Available data on prescription records include the National 
Drug Code (NDC) as well as the quantity of the medication dispensed.  Charge, 
allowed and paid amounts are available for all services rendered, as well as dates of 
service for all claims.  Additional data elements include demographic variables (age, 
gender, geographic region), product type (e.g., HMO, PPO), payer type (e.g., 
commercial, self-pay), provider specialty, and start and stop dates of health-plan 
enrollment.   
Sample Selection:   
The  sample consisted of patients aged 16-76 years newly identified as tobacco 
dependent who had smoking related cancer as defined by presence of a diagnosis code 
for tobacco use disorder and/or CPT code for tobacco cessation counseling, advice or 
treatment (Appendix) during the index period July 2010 to June 2011 (index).  
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Because of low cancer event rate and the assumption that diagnoses of smoking 
related cancer and tobacco dependence within approximately 2 years of each other 
were related, the identification period for a smoking related cancer diagnosis 
(Appendix) was anytime in the study period January 2009 to June 2012.  Patients with 
ICD-9 or CPT codes related to tobacco dependence in the lookback period January 
2009 through June 2010 were excluded (Figures 1, 2).  Charlson Comorbidity Index 
(CCI) scores for each patient were calculated using the algorithm develop by Quan, et 
al., through identification of ICD-9 codes related to 17 co-morbidity categories in the 
12 month period prior (pre-index) to and 12 month period after the index date 
(including index date).  Weights specific to each co-morbidity category were assigned 
and the CCI score calculated; higher scores indicate greater co-morbidity.9   
Statistical Analysis: Descriptive statistics were used to describe demographic and 
clinical characteristics and frequency of prescription of SCM defined as 1 or more 
claims for varenicline, bupropion SR or NRT during the study period January 1, 2009–
June 30, 2012.  Demographic characteristics included patient age at index, gender, 
geographic region of residence and insurance related factors such as payer type and 
insurance product.  Clinical characteristics included  12 month pre-index CCI score 
and CCI categories.  Provider characteristics included the practitioner type associated 
with diagnosis of or counseling/advice for tobacco dependence. Patients were 
categorized into one of two groups, those who were prescribed SCM at any time 
during the study period and those who were not. Bivariate analyses including t-tests 
for continuous variables and chi-square tests or Fisher’s Exact test for categorical 
variables were used to analyze differences in patient characteristics.  Assessment of 
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factors associated with  SCM prescription was performed by conducting a series of 
univariate logistic regression equations. To qualify for multivariate logistic regression, 
variables had to be associated with SCM prescription in the univariate analyses 
(p<0.2) or be otherwise clinically important.  Multivariate logistic regression was used 
to assess relationships between the independent variables of patient and provider 
characteristics and the dependent variable   SCM prescription at any time during the 
study period.  The model was created using a backward elimination process and the 
likelihood ratio test and AIC used to assess the model at each step, removing least 
statistically significant covariates (p>0.05) with each iteration and evaluating 
differences between full and reduced models for statistical significance.  In advance of 
model inclusion, multicollinearity among independent variables was assessed.  
Multicollinearity was assessed by regressing independent variables against the 
independent variable of patient age at index.  Main effects and two factor interactions 
of independent variables found significant in the model were assessed. The Hosmer-
Lemeshow test was used to assess goodness of fit of the final model.  The measure of 
effect is presented as an odds ratio with corresponding 95% confidence intervals. All 
analyses were conducted using SAS® Version 9.4 (SAS Institute, Cary, NC) with 
statistical significance defined as p <0.05.  Analyses were performed using a 2-tailed 
alpha of .05 and 95% confidence intervals calculated.   
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Results 
In total, 324 newly identified tobacco dependent patients with a smoking related 
cancer were identified. Mean (SD) age at index was 58.51 years (10.38), 56.48% were 
male and 66.05% resided in the Midwest.  The most common payer type was 
commercial in 75% of patients (Table 1). Mean (SD) pre-index CCI was 2.82 (±3.07) 
and 43.21% were diagnosed with or counseled for tobacco cessation by a hospital 
related department or practitioner.  The most common pre-index Charlson 
comorbidities were cancer in 56.48% of patients and COPD in 21.6% patients.  Mean 
(SD) CCI score in the 12 months following diagnosis was 5.08 (±3.19) and the 
occurrence of the Charlson co-morbidity of cancer in the 12 months following 
diagnosis (data not shown) was observed in all patients (Table 2).  Lung cancer was 
the most common tumor type in 79 patients (24.38%) (Table 3).   
Of the diagnosed sample with a smoking related cancer, 46 patients (14.2%) were 
treated with SCM during the study period.  Of treated patients, mean (SD) age was 
56.30 (8.94) years and 50% were male.  Patients aged 50-64 were >3 times more 
likely to be prescribed SCM than their younger or older counterparts (44.08% vs. 
13.73% in age 20-49; 8.60% age ≥65 years).  The majority of treated patients resided 
in the East (22.58% vs. 16.82 in the Midwest; 3.85% in the South) (Table 1).  
Compared to other tumor types, patients with lung cancer had the highest rate of SCM 
prescription (21.52%) (Table 3). 
In multivariate regression analysis, patients diagnosed by a hospital related 
practitioner had lower odds of receiving SCM (OR 0.319, 95% CI 0.149-0.686).  After 
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multivariate analysis, age, patient gender, pre-index CCI score  and payer type were 
not significant. 
 
Discussion 
Tobacco smoking is known to increase the risk of numerous cancers and despite 
declines in smoking rates over the past few decades,  recent estimates suggest that  
half of deaths in the US due to 12 cancer types are smoking related.9  Clinical practice 
guidelines and quality measures encourage tobacco cessation efforts in patients with 
cancer,  and this study provides data that addresses the extent to which these 
guidelines have been implemented.3,5   Our results suggest that 14.2% of tobacco 
dependent patients with smoking related cancers were treated with SCM.   
Due to paucity of data regarding rates of SCM use in cancer patients or the 
general population of tobacco dependent persons and differences in study designs, it is 
difficult to compare our findings to those of other studies.  However, some insight into 
the rate of SCM use in cancer patients is informed by a survey of physicians caring for 
lung cancer patients who reported belief that tobacco cessation is a necessary part of 
clinical care, but who also reported low rates of providing patients with assistance in 
this regard.10  Of note, >20% reported rarely or never discussing medication options 
with their patients during the initial visit, while approximately 15% reported always 
doing so and almost one-third discussing medication options some of the time.10  
However, it is not known if these physicians’ patients received SCM related 
counseling from their non-oncology providers.  
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Of note, compared to general medicine practitioners, tobacco dependence 
diagnosis or procedure by a hospital related practitioner was associated with lower 
odds of treatment with SCM (OR 0.319, 95% CI 0.149-0.686).  Hospitalization is an 
opportunity for patients to attempt to quit tobacco as they are likely to be in a smoke-
free environment and may be particularly motivated by an illness caused or 
exacerbated by tobacco use.11  Patients can be encouraged to remain smoke free after 
discharge and begin treatment in the hospital. In a meta-analysis of randomized 
controlled trials of smokers hospitalized for a CVD diagnosis, a smoking cessation 
intervention begun in the hospital and sustained for at least 1 month post-discharge, 
increased cessation rates by 42% (RR: 1.42, 95% CI: 1.29–1.56) during the 6-12 
months period post-discharge and starting NRT in hospital increased quit rates over 
counseling alone.12   Furthermore, in a trial of smokers hospitalized with MI,  
compared to usual care, intensive intervention with counseling and pharmacotherapy 
increased cessation rates and reduced all-cause mortality and hospital readmission.13  
Of note, it appears as though diagnosis of or counseling/advice for tobacco 
dependence may have been co-incident with a tobacco related co-morbidity as mean 
CCI score post-index was nearly twice that of the pre-index mean (5.08 vs. 2.82, 
respectively) and the Charlson co-morbidity category of cancer was present in 56.48% 
of patients prior to diagnosis and 100% post-index. 
Finally, it is clear that tobacco cessation efforts need to be targeted earlier to 
prevent clinical sequelae including cancer.  Janjigian, et al found that 70% of NSCLC 
patients had a smoking history of >15 pack years.14 Quitting smoking reduces cancer 
risk and estimates are that five years after quitting, the risk of cancers of the mouth, 
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throat, esophagus, and bladder is cut in half and after 10 years, the risk of dying from 
lung cancer is about half that of a person who is still smoking.15 The risks of cancer of 
the larynx (voice box) and pancreas are also reported to decrease.15   
This study utilized data from medical and pharmacy claims which are collected 
for billing and reimbursement purposes and which have inherent limitations. Data 
entry errors at sites of care cannot be detected or corrected in data analysis. Although 
data used in this study were collected from all U.S. census regions, due to geographic 
biases, any unprojected geographic information may not be representative of the true 
distribution. Finally, the small number of patients in some subgroups evaluated 
precludes comparisons by statistical analysis and thus, results are descriptive in nature.  
The requirement for continuous enrollment may bias the results due to lack of 
ascertainment of mortality in a population of patients with higher mortality risk than 
the general population.  In general, expected cancer survival rates are longer when 
disease is detected at earlier stages but ascertainment of cancer stage is not possible in 
claims data.  These results should be considered generalizable to an insured US 
population with a smoking related cancer who have been diagnosed as tobacco 
dependent or counseled/advised about smoking cessation and whose clinical or other 
circumstances may be associated with survival. 
It is also important to note that though patients were identified as smokers 
through diagnosis or procedure codes, this provides no insight into readiness to quit 
which is an important component of cessation attempts.11 Also, only prescription 
versus over the counter (OTC) SCM could be captured and payment of a prescription 
claim does not mean that a patient took the medication as prescribed.  Because 
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medications available OTC do not commonly exist in research databases, it is difficult 
to estimate the extent to which OTC NRT is used.  Results of an international survey 
of smokers indicated that 68.3% of subjects self-report OTC NRT use.  Of note, those 
who obtained OTC NRT appeared more likely to discontinue in the first week of use 
than those receiving NRT by prescription (23% vs. 13.4%, respectively.)16  These data 
also do not represent those prescriptions that may have been written but not filled by 
the patient.  . Patients may have quit smoking, but clinical outcomes of this nature are 
not ascertainable in administrative claims data. Thus, treatment rates may be 
underestimated in this sample 
Finally, misclassification of a cancer diagnosis as smoking related is possible, but 
identification of tobacco dependence diagnosis or procedure was performed to ensure 
that patients were smokers.  Though not known, it is probable that a diagnosis of 
tobacco dependence does not take place in all smokers so the sample may be 
underrepresentative.  Future research using a larger dataset could study this issue by 
indexing on a smoking related cancer diagnosis and exploring use of SCM in these 
patients.  In addition, there is need for a prospective cohort study that would include 
real time smoking data.   
Despite limitations, this study adds important information regarding the use of 
SCM in patients with cancer.  Tobacco dependence or counseling/advice for smoking 
cessation in these patients was likely coincident or following diagnosis of comorbidity 
and earlier such intervention may be warranted. Diagnosis or counseling in a hospital 
could capture patients at a time when cessation efforts such as initiating SCM have 
been shown to be effective.   
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Table 3.1. Rate of SCM Use by Demographic Characteristics among Tobacco 
Dependent Patients with Smoking Related Cancer, LifeLink™ Health Plan 
Claims Database, (July 2010-June 2011)                                                   
*Results presented only for SCM Rx counts >5 
Rx=dispensed prescription, HMO=health maintenance organization, POS=place of service 
 
  Total   
(N =324 ) 
 
No Rx for SCM in 
study period (n=278) 
Rx for SCM in 
study period 
(n=46) 
 
p-value 
Age at index, years, 
mean, (SD)  58.51 (10.38) 
58.88 (10.57) 56.30 (8.94) 0.1197 
Age Category, No. (%)  
 
 
 
0.0464 
Ref=20-49    
20-49 51 (15.74) 44 (86.27) 7 (13.73) 
50-58 94 (29.01) 73 (77.66) 21 (22.34) 
59-64 86 (26.54) 76 (88.37) 10 (21.74) 
65-75 93 (28.70) 85 (91.40) 8 (8.60)  
Gender, No. (%)  
Female 141 (43.52) 118 (83.69) 23 (16.31)  
0.3385 Male 183 (56.48) 160 (87.43) 23 (12.57) 
Patient Geographic Region, No. (%) 
East 31 (9.57) 24 (77.42) 7 (22.58)  
 
<0.05 Midwest 214 (66.05) 178 (83.18) 36 (16.82) 
South ≤5 (1.54) ≤5 (≤100) 0 
West 78 (24.07) ≤77 (≤98.72)  ≤5 (≤6.41) 
Product Type , No. (%)* 
HMO   249 (76.85) 
210 (84.34) 39 (15.66)  
0.3922 
POS   114 (35.19) 99 (86.84) 15 (13.16) 0.6928 
Payer Type, No (%)* 
   
Commercial 243 (75.00) 
202 (83.13) 41 (16.87) 0.0169 
Medicare 64 (19.75) 34 (53.13) 30 (46.88) ns 
Self-insured   47 (14.51) 41 (87.23) 6 (12.77) 0.7610 
Pharmacy Benefit 267 (82.41) 224 (83.90) 43 (16.10) 0.0333 
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Table 3.2. Rate of SCM Use by Clinical Characteristics and Diagnosing Specialty 
among Patients Tobacco Dependent Patients with Smoking Related Cancer, 
LifeLink™ Health Plan Claims Database, (July 2010-June 2011)              
 
*Results presented only for SCM counts >5 
**Multiple specialties diagnosing the patient on the same date possible, Rx=dispensed prescription, 
HMO=health maintenance organization, POS=place of se rvice, PPO=preferred provider organization, 
HIV/AIDS=Human immunodeficiency Virus/Acquired Immunodeficiency Syndrome, GP=general 
practice, FP=family practice, NP=nurse practitioner, Ob/Gyn=obstetrics & gynecology, PA=physician’s 
assistant, ER=emergency room, pulm=pulmonogist, onc=oncologist, endo=endocrine, ENT=ear, nose 
& throat, gastro=gastroenterologist, ID=infectious disease, nephro=nephrologist, neuro=neurologist, 
ophth=ophthalmologist, optom=optometrist, phys med= physical medicine, pscych=psychiatrist, 
rheum=rheumatologist, urol=urologist, DM_HH=durable medical equipment/home health, PT=physical 
therapist, RN=registered nurse, SOC_WORK=social worker, MHSA_FAC=mental health/substance 
abuse facility 
  Total   
(N =324 ) 
No Rx for SCM in study 
period (n=278) 
Rx for SCM in 
study period 
(n=46) 
p-
value 
Charlson Comorbidity Index (CCI), 
mean, (SD) in 12 months pre-index 2.82 (3.07) 
2.94 (3.13) 2.09 (2.58) 0.0800 
Pre-index CCI  0-1, n (%)  120 (37.04) 99 (82.50) 21 (17.50)  
 
0.0848 Pre-index CCI  2-3, n (%) 119 (36.73) 100 (84.03) 19 (15.97) 
Pre-index CCI  ≥4, n (%) 85 (26.23) 
79 (92.94) 6 (7.06) 
Charlson Comorbidity Index, mean, 
(SD) during 1 year follow up period 5.08 (3.19) 
5.08 (3.18) 5.11 (3.29) 0.9537 
CCI follow up 2, n (%) 93 (28.70) 79 (84.95) 14 (15.05)  
 
0.7150 CCI follow up 3-4 , n (%) 91 (56.79) 79 (86.81) 12 (13.19) 
CCI follow up 5-8, n (%) 72 (22.22) 64 (88.89) 8 (11.11) 
CCI follow up 9-14 , n (%) 68 (20.99) 56 (82.35) 12 (17.65) 
Pre-index CCI categories*  n=324 
COPD 70 (21.60) 60 (85.71) 10 (14.29) 1.00  
Cancer 183 (56.48) 163 (89.07) 20 (10.93) 0.0765 
PVD 31 (9.57) 26 (83.87) 5 (16.13) 0.7861 
Diagnosing Specialty Type**  No. (%)  
General Medicine (GP/FP, Internal 
Med, NP, Ob/Gyn, Osteopath, PA) 133 (41.05) 
106 (79.70) 27 (20.30) 0.0099 
Hospital Related Practitioner (surgical, 
ER, hospital, anesthesia, Orthopedics) 140 (43.21) 
128 (91.43) 12 (8.57) 0.0153 
Specialist (e.g., cardiologist, pulm,onc, 
endo, ent, gastro,ID,allergist, nephro, 
neuro, ophth, optom,phys med, 
podiatry, psych,rheum,urol) 
59 (18.21) 
 
 
51 (86.44) 
 
 
8 (13.56) 
 
 
1.00  
Other (DME_HH, PT, RN, 
SOC_WORK, MHSA_FAC) 12 (3.70) 
12 (100) 0  
Prescription with SCM in Study Period 
No. (%) 46 (14.2%) 
   
Prescription with SCM both pre-index 
and post-index No. (%) 10 (0.31%) 
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Table 3.3.  Rate of SCM Use by Tumor Type in  Patients Diagnosed with Tobacco 
Dependence, LifeLink™ Health Plan Claims Database  (July 2010-June 2011)                          
(n=324)* 
 Tumor type  
 
No SCM Rx 
(n=278) 
SCM Rx 
n=46) 
p-value 
Any  324 (100) 278 (85.80) 46 (14.20) 0.1116 
Bladder 50 (15.43) 43 (86.00) 7 (14.00) 0.9653 
Colorectal cancer 59 (18.21) 53 (89.83) 6 (10.17) 0.3270 
Head and Neck 50 (15.43) 44 (88.00) 6 (12.00) 0.6283 
Kidney 40 (12.35) 34 (85.00) 6 (15.00) 0.8766 
Lung 79 (24.38) 62 (78.48) 17 (21.52) 0.0320 
*Results presented only for SCM Rx counts >5 
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Table  3.4.   Summary of Logistic Regression Analysis of Predictors of Treatment 
with SCM in Tobacco Dependent Patients with Smoking Related Cancer: Odds 
Ratios and 95% Confidence Intervals  
Independent variable Odds Ratio  95% Wald CI p-value 
Age 50-58 years 
(reference = 20-49 years) 
1.810 0.694-4.725 0.2254 
Age 59-64 years  
(reference = 20-49 years) 
0.828  0.288 -2.384 0.7272 
Age >65 years  (reference = 20-49 years) 0.539 0.179 – 1.618 0.2702 
Diagnosis by disease specialist, 
pediatrician, non-physician 
0.4670 0.232 – 1.445 0.2415 
Diagnosis by hospital related practitioner 0.319 0.149 – 0.686 0.0034 
Hosmer- Lemeshow Goodness of Fit Test p = 0.9016 
CI=confidence interval 
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Figure 3.1.  Sample Selection Diagram– Tobacco Dependent Patients with 
Smoking Related Cancers and Treatment with SCM (January 2009-June 
2012) 
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Figure 3.2.  Sample Selection Flow– Tobacco Dependent Patients with Smoking 
Related Cancers and Treatment with SCM (January 2009-June2012)…………… 
 
LifeLink™ Health Plan Claims Database enrolled patients:  N=18,400,000 as of August 2012* 
 
Continuously enrolled patients January 2009 – June 2012  
Patients aged 16-76 identified as having any tobacco related diagnoses or procedure, SCM or smoking 
related cancers  
n = 117,695  
 
Patients identified as having any tobacco related diagnoses or procedures or smoking related cancers 
(Patient count without smoking cessation treatment)    
n=80,486  
 
Patients enrolled January 2009 to June 2012 with a diagnosis or procedure indicating tobacco 
dependence (Patient count without smoking related cancer) 
n=77,736 
 
 Patients with a diagnosis or procedure code indicating tobacco dependence between July 2010 
and June 2011 (index) 
n=18,619 
 
Patients with a diagnosis or procedure code indicating tobacco dependence between July 2010 and June 
2011 with claims activity throughout the study period (January 2009 – June 2012)  
n=16,417  
 
 Patients with a diagnosis or procedure indicating tobacco dependence between July 2010 and 
June 2011 with claims activity throughout the study period (January 2009 - June 2012) and a diagnosis 
of smoking related cancer (January 2009 - June 2012) 
n=324   
 
 No Treatment with SCM in pre or post 
index periods 
 (January 2009-June 2012) 
n = 278 
 
Treatment with SCM in pre or post index periods  
(January 2009-June 2012) 
n = 46 
 
*Closest estimate for continuously enrolled patients during the study period  is 18.4MM patients as of 
August 2012.  Enrollment is subject to change quarterly as updates are received from contributing 
health plans.  Largest changes are typically seen at year beginning when patients may leave a health 
plan and join another.  The data used for this study has been merged into a new larger database called 
Pharmetrics Plus which includes a larger number of contributing health plans.  The database that 
includes the data used for this study is archived and would require data restoration  to determine exact 
count. 
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CONCLUSION 
 
The 3 studies presented herein provide insight into the utility of using 
administrative claims data to study patients who are tobacco dependent and their 
treatment with SCM.  Taken in their entirety, these studies’ findings contribute certain 
apparent overarching themes and other important observations.   
 
Keeping in mind the stated limitation of 18 month claims history and possibility 
that patients may have been diagnosed, counseled or treated for tobacco dependence 
prior to index in these studies, it seems apparent that the health system is identifying -
patients as tobacco dependent co-incident with identification of other co-morbidity.  
This is evident in the first manuscript through the 34% change in CCI from the pre- to 
the post-index period and in the third study which observed a near doubling of CCI in 
cancer patients after newly being identified or counseled as tobacco dependent.  As 
stated, early intervention and management of tobacco dependence is likely the best 
strategy to aid patients in what is likely to be multiple attempts to quit smoking.   
The second theme is related to practitioner type diagnosing or counseling 
patients.  Diagnosis or counseling by a hospital related practitioner was associated 
with reduced likelihood of SCM treatment as an outpatient overall and in patients with 
smoking related cancer.  Joint Commission core measures include counseling for 
tobacco dependence in inpatients, but these efforts may not be continued after patients 
are discharged from the hospital.  However, it is not known if patients obtained OTC 
NRT following discharge or if the important factor of change readiness to embark on a 
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quit effort was present.  Though these variables are not observable in claims data, 
perhaps identification of patients in this manner could serve as indicators for future 
follow up after discharge.  Similarly, diagnosis by a therapeutic area specialist was 
associated with lower likelihood of SCM prescription and it has been recognized in the 
literature that management of tobacco dependence can be a major contributor to risk of 
events often managed by therapeutic area specialists, e.g., cardiologists and 
oncologists, and that specialists are in unique position to aid patients in their quit 
efforts.  Management of smoking cessation should not be considered a primary care 
issue, but an opportunity for intervention at any health care professional interaction.   
Another theme is consideration of baseline co-morbidity and relationship to use 
of SCM.  In the first study, use of SCM was low in those with cancer or MI at baseline 
and patients with cancer diagnosis at baseline had reduced odds of SCM prescription.  
Interestingly, this finding exists in parallel to the finding of reduced odds of SCM use 
in patients diagnosed or counseled by therapeutic area specialists.  Of note, patients 
with HIV/AIDS had the highest rates of SCM prescription which is encouraging given 
the additional risk of smoking in these patients, but generalizability to a routine 
Medicaid population from these data obtained from commercial health plans must be 
considered.    
The premature discontinuation rate observed in the second study exceeded 90% 
and studies exist that have varied designs and descriptions of the relationship of 
duration of therapy and quit outcomes with some studies finding quitting success with 
shorter durations than 12 weeks and others suggesting that longer durations of SCM 
therapy yields better quit outcomes.  Considering that patients may experience reduced 
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cravings and nicotine withdrawal symptoms relatively early in SCM therapy, 
consideration should be given to counseling patients at the outset and throughout 
therapy regarding their possible perception that they no longer need therapy 
juxtaposed with information from labeled instructions describing recommended 
duration of use.     
Differences in SCM use by age were also observed with the youngest and oldest 
patients being less likely to receive SCM prescription and patients over age 50 years 
having lower likelihood of premature discontinuation.  Consideration of differences in 
readiness to change by patients who may have yet experienced a smoking related 
comorbidity and in those who may be resistant to changing longstanding behaviors is 
important.  Recent action by the American Academy of Pediatrics suggests 
consideration of SCM use in younger people depending on their readiness to change 
and extent of tobacco dependence.    Moreover, older patients can still be motivated to 
change and advanced age should not serve as a barrier to use of SCM.  
Lastly, certain factors not studied here are important to consider for future study 
including combination use of SCM agents, exploration of mental health factors related 
to tobacco dependence diagnosis or counseling and SCM use and exploration of larger 
datasets with longer study periods.  
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APPENDICES 
Table A.1.1  Tobacco Dependence Related Diagnosis and Procedure Codes 
 
Diagnosis or 
Procedure Code 
Code and Description 
ICD-9  305.1 Tobacco use disorder  
989.84 Toxic effect of other substances, chiefly nonmedicinal as to source, tobacco 
649.0x Tobacco use disorder complicating pregnancy, childbirth, or puerperium  
V1582 History of tobacco use (personal history of tobacco use) 
HCPCS/CPT 99406 Smoking and tobacco-use cessation counseling visit; intermediate, greater 
than 3 minutes up to 10 minutes.  
99407 Smoking and tobacco-use cessation counseling visit; intensive, greater than 
10 minutes.  
S9075 Smoking Cessation Treatment  
S9453 Smoking Cessation Classes, non-physician provider, per session  
1032F Current tobacco smoker or currently exposed to secondhand smoke (asthma) 
1033F Current tobacco non-smoker and not currently exposed to secondhand 
smoke (asthma) 
1034F Tobacco - current smoker 
1035F Current smokeless tobacco user (chew, snuff) 
4000F Tobacco use cessation intervention, counseling 
4001F Tobacco use cessation intervention, pharmacologic therapy 
4004F  Patient screened for tobacco use and received tobacco cessation 
intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user 
C9801  Smoking and tobacco cessation counseling visit for the asymptomatic 
patient intermediate, greater than 3 minutes, up to 10 
C9802 Smoking and tobacco cessation counseling visit for the asymptomatic 
patient intensive, greater than 10 minutes 
G0375 Smoking and tobacco use cessation counseling visit; intermediate, greater 
than 3 minutes up to 10 minutes 
G0376 Smoking and tobacco use cessation counseling visit; intensive, greater 
than 10 minutes 
G0436 Smoking and tobacco cessation counseling visit for the asymptomatic 
patient; intermediate, greater than 3 minutes, up to 10 minutes 
G0437 Smoking and tobacco cessation counseling visit for the asymptomatic 
patient; intensive, greater than 10 minutes 
G8402 Tobacco (smoke) use cessation intervention, counseling 
G8403 Tobacco (smoke) use cessation intervention not counseled 
G8453 Tobacco use cessation intervention, counseling 
G8454 Tobacco use cessation intervention not counseled, reason not specified 
G8455 Current tobacco smoker 
G8456 Current smokeless tobacco user 
G8686 Currently a tobacco smoker or current exposure to secondhand smoke 
G8688 Currently a smokeless tobacco user (eg, chew, snuff) and no exposure to 
secondhand smoke 
G8690 Current tobacco smoker or current exposure to secondhand smoke 
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Table A.1.2.  Charlson Co-morbidity Index Codes 
 
 
 
 
 
 
 
Co-morbidity Codes  
Chronic pulmonary disease 490.x-496.x, 500.x-505.x, 416.8, 416.9, 506.4, 508.1, 508.8  
Diabetes without chronic 
complications 
250.0-250.3 
Any malignancy, including 
lymphoma and leukemia, 
except neoplasm of skin 
140.x-165.x, 170.x-172.x, 174.x-176.x, 179.x, 180.x-195.x, 200.x-
208.x 
Mild liver disease 070.22, 070.23, 070.32, 070.33, 070.44, 070.54, 070.6, 070.9, 
570.x, 571.x, 573.3, 573.4, 573.8, 573.9, V42.7 
 
Peripheral Vascular Disease 440.x, 441.x, 0930, 4373, 443.1, 443.2, 443.8, 443.9, 447.1, 557.1, 
557.9, V43.4  
Cerebrovascular Disease 430.x-438.x, 362.34 
Diabetes with chronic 
complications 
250.4-250.9 
Rhuematic Disease 446.5, 710.0-710.4, 714.0- 714.2, 714.8, 725 
Congestive Heart Failure 428.x,425.4-425.9, 398.91, 402.91, 402.11, 404.01, 404.03, 404.11, 
404.13, 404.91, 404.93 
 
Myocardial infarction  410.x, 412.x 
Renal Disease 403.01, 403.11, 403.91, 404.02, 404.03, 404.12, 404.13, 404.92, 
404.93, 582.x, 585.x, 586.x V56.x 
583.0-583.2, 583.4, 583.6-583.7, 588.0, V420, V451 
Metastatic cancer 196.x-199.x 
Hemiplegia or paraplegia 334.1, 342.x, 343.x, 344.0-344.6, 344.9 
 
Peptic ulcer disease 531.x-534.x 
Moderate to severe liver 
disease 
456.0-456.2, 572.2-572.4, 572.8 
HIV/AIDS 042.x-044.x 
Dementia 290.x, 294.1, 331.2  
 78 
 
Table A.1.3.  Select CCI categories Pre-index  and During Follow-up Periods – 
All diagnosed patients (n=15000), LifeLink™ Health Plan Claims Database   
(July 2010-June 2011)                         
CCI 
Category, 
No. (%) 
During 12 
months 
pre-index 
only 
In 1yr follow 
up only 
Both Pre-index  and 
Follow-up 
Difference p - value 
COPD 705 (4.70) 1657 (11.05) 1187 (7.91) 135% <0.0001 
Diabetes 170 (1.13) 412 (2.75) 1130 (7.53) 142% <0.0001 
Cancer 107 (0.71) 314 (2.09) 533 (3.55) 193% <0.0001 
PVD 179 (1.19) 394 (2.63) 226 (1.51) 120% <0.0001 
CVD 183 (1.22) 394 (2.63) 163 (1.09) 115% <0.0001 
CHF 82 (0.55) 215 (1.43) 144 (0.96) 162% <0.0001 
MI 88 (0.59) 235 (1.57) 90 (0.60) 157% <0.0001 
Metastatic 
cancer 
36 (0.24) 108 (0.72) 34 (0.23) 200% <0.0001 
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Table A.1.4.  Results of Test for Multicollinearity Among Independent Variables 
Selected for Multivariate Logistic Regression – Predictors of SCM Use in 
Tobacco Dependent Patients, LifeLink™ Health Plan Claims Database  (July 
2010-June 2011) 
Regression Against Patient Age at Index 
Independent Variable Variance Inflation Factor Condition Index 
Payer Type Medicare Supplemental 1.072 1.522 
Payer Type Medicare Advantage 1.367 1.736 
Payer Type Medicaid 1.994 1.774 
Payer Type Self-insured 1.665 1.845 
Payer Type Commercial 2.669 1.868 
Diagnosing Practitioner Type 
General Medicine 
4.399 1.900 
Diagnosing Practitioner Type 
Hospital Related 
3.808 1.912 
Diagnosing Practitioner Type 
Pediatrics 
1.097 1.922 
Diagnosing Practitioner Type 
Therapeutic Area Specialist 
1.971 1.940 
Diagnosing Practitioner Type Other 1.161 1.952 
CHF diagnosis in 12 months pre-
index 
1.087 1.992 
MI diagnosis in 12 months pre-
index 
1.065 2.020 
Cancer diagnosis in 12 months pre-
index 
1.025 2.065 
Diabetes diagnosis in 12 months 
pre-index 
1.208 2.129 
Renal Disease diagnosis in 12 
months pre-index 
1.215 2.198 
Mild liver disease diagnosis in 12 
months pre-index 
1.068 2.318 
HIV-AIDS diagnosis in 12 months 
pre-index 
1.020 2.546 
Ulcer diagnosis in 12 months pre-
index 
1.004 7.550 
CHF diagnosis in 12 months pre-
index 
1.005 13.569 
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Table A.2.1. Results of Test for Multicollinearity Among Independent Variables 
Selected for Multivariate Logistic Regression Model – Predictors of Premature 
SCM Discontinuation  
Regression Against Patient Age at Index 
Independent Variable Variance Inflation Factor Condition Index 
Payer Type Medicare Supplemental 1.205 1.637 
Payer Type Medicare Advantage 1.064 1.908 
Payer Type Medicaid 2.373 1.951 
Payer Type Self-insured 2.187 2.123 
Payer Type Commercial 2.559 2.147 
Insurance Product HMO 1.630 2.157 
Insurance Product PPO 2.420 2.212 
Insurance Product POS 1.710 2.270 
Insurance Product Consumer 
Directed 
1.028 2.392 
Insurance Product Indemnity 1.121 2.460 
Diagnosing Practitioner Type 
General Medicine 
3.412 3.198 
Diagnosing Practitioner Type 
Therapeutic Area Specialist 
1.817 4.404 
Diagnosing Practitioner Type 
Hospital Related 
2.540 6.529 
Diagnosing Practitioner Type 
Pediatrics 
1.111 9.487 
Diagnosing Practitioner Type Other 1.185 15.514 
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Table A.2.2.  .  Results of Test for Multicollinearity Among Independent Variables 
Selected for Multivariate Logistic Regression Model - Predictors of Repeat 
Treatment with SCM 
 
Regression Against Patient Age at Index 
Independent Variable Variance Inflation Factor Condition Index 
Insurance Product HMO 1.444 1.706 
Insurance Product PPO 1.084 1.824 
Insurance Product POS 1.496 1.837 
Insurance Product Consumer 
Directed 
1.022 1.864 
Insurance Product Indemnity 1.062 1.887 
Diagnosing Practitioner Type 
General Medicine 
3.393 1.956 
Diagnosing Practitioner Type 
Therapeutic Area Specialist 
1.784 2.000 
Diagnosing Practitioner Type 
Hospital Related 
2.536 2.486 
Diagnosing Practitioner Type 
Pediatrics 
1.108 5.586 
Diagnosing Practitioner Type Other 1.177 11.413 
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Table A.3.1.  ICD-9 Codes and Descriptions – Smoking Related Cancers 
 
TUMOR TYPE TUMOR 
SUB-TYPE 
CODE CODE DESCRIPTION 
Head & Neck Cancer  140 140 Malignant neoplasm of lip 
Head & Neck Cancer  1400 140.0 Malignant neoplasm of 
upper lip, vermilion border 
Head & Neck Cancer  1401 140.1 Malignant neoplasm of 
lower lip, vermilion border 
Head & Neck Cancer  1403 140.3 Malignant neoplasm of 
upper lip, inner aspect 
Head & Neck Cancer  1404 140.4 Malignant neoplasm of 
lower lip, inner aspect 
Head & Neck Cancer  1405 140.5 Malignant neoplasm of lip, 
inner aspect, unspecified as 
to upper or lower 
Head & Neck Cancer  1406 140.6 Malignant neoplasm of 
commissure of lip 
Head & Neck Cancer  1408 140.8 Malignant neoplasm of 
other sites of lip 
Head & Neck Cancer  1409 140.9 Malignant neoplasm of lip, 
vermilion border, 
unspecified as to upper or 
lower 
Head & Neck Cancer  141 141 Malignant neoplasm of 
tongue 
Head & Neck Cancer  1410 141.0 Malignant neoplasm of base 
of tongue 
Head & Neck Cancer  1411 141.1 Malignant neoplasm of 
dorsal surface of tongue 
Head & Neck Cancer  1412 141.2 Malignant neoplasm of tip 
and lateral border of tongue 
Head & Neck Cancer  1413 141.3 Malignant neoplasm of 
ventral surface of tongue 
Head & Neck Cancer  1414 141.4 Malignant neoplasm of 
anterior two-thirds of 
tongue, part unspecified 
Head & Neck Cancer  1415 141.5 Malignant neoplasm of 
junctional zone of tongue 
Head & Neck Cancer  1416 141.6 Malignant neoplasm of 
lingual tonsil 
Head & Neck Cancer  1418 141.8 Malignant neoplasm of 
other sites of tongue 
Head & Neck Cancer  1419 141.9 Malignant neoplasm of 
tongue, unspecified site 
Head & Neck Cancer  143 143 Malignant neoplasm of gum 
Head & Neck Cancer  1430 143.0 Malignant neoplasm of 
upper gum 
Head & Neck Cancer  1431 143.1 Malignant neoplasm of 
lower gum 
Head & Neck Cancer  1438 143.8 Malignant neoplasm of 
other sites of gum 
Head & Neck Cancer  1439 143.9 Malignant neoplasm of 
gum, unspecified site 
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TUMOR TYPE TUMOR 
SUB-TYPE 
CODE CODE DESCRIPTION 
Head & Neck Cancer  144 144 Malignant neoplasm of floor 
of mouth 
Head & Neck Cancer  1440 144.0 Malignant neoplasm of 
anterior portion of floor of 
mouth 
Head & Neck Cancer  1441 144.1 Malignant neoplasm of 
lateral portion of floor of 
mouth 
Head & Neck Cancer  1448 144.8 Malignant neoplasm of 
other sites of floor of mouth 
Head & Neck Cancer  1449 144.9 Malignant neoplasm of floor 
of mouth, part unspecified 
Head & Neck Cancer  145 145 Malignant neoplasm of 
other and unspecified parts 
of mouth 
Head & Neck Cancer  1450 145.0 Malignant neoplasm of 
cheek mucosa 
Head & Neck Cancer  1451 145.1 Malignant neoplasm of 
vestibule of mouth 
Head & Neck Cancer  1452 145.2 Malignant neoplasm of hard 
palate 
Head & Neck Cancer  1453 145.3 Malignant neoplasm of soft 
palate 
Head & Neck Cancer  1454 145.4 Malignant neoplasm of 
uvula 
Head & Neck Cancer  1455 145.5 Malignant neoplasm of 
palate, unspecified 
Head & Neck Cancer  1456 145.6 Malignant neoplasm of 
retromolar area 
Head & Neck Cancer  1458 145.8 Malignant neoplasm of 
other specified parts of 
mouth 
Head & Neck Cancer  1459 145.9 Malignant neoplasm of 
mouth, unspecified site 
Head & Neck Cancer  146 146 Malignant neoplasm of 
oropharynx 
Head & Neck Cancer  1460 146.0 Malignant neoplasm of 
tonsil 
Head & Neck Cancer  1461 146.1 Malignant neoplasm of 
tonsillar fossa 
Head & Neck Cancer  1462 146.2 Malignant neoplasm of 
tonsillar pillars (anterior) 
(posterior) 
Head & Neck Cancer  1463 146.3 Malignant neoplasm of 
vallecula 
Head & Neck Cancer  1464 146.4 Malignant neoplasm of 
anterior aspect of epiglottis 
Head & Neck Cancer  1465 146.5 Malignant neoplasm of 
junctional region of 
oropharynx 
Head & Neck Cancer  1466 146.6 Malignant neoplasm of 
lateral wall of oropharynx 
Head & Neck Cancer  1467 146.7 Malignant neoplasm of 
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TUMOR TYPE TUMOR 
SUB-TYPE 
CODE CODE DESCRIPTION 
posterior wall of oropharynx 
Head & Neck Cancer  1468 146.8 Malignant neoplasm of 
other specified sites of 
oropharynx 
Head & Neck Cancer  1469 146.9 Malignant neoplasm of 
oropharynx, unspecified site 
Head & Neck Cancer  147 147 Malignant neoplasm of 
nasopharynx 
Head & Neck Cancer  1470 147.0 Malignant neoplasm of 
superior wall of 
nasopharynx 
Head & Neck Cancer  1471 147.1 Malignant neoplasm of 
posterior wall of 
nasopharynx 
Head & Neck Cancer  1472 147.2 Malignant neoplasm of 
lateral wall of nasopharynx 
Head & Neck Cancer  1473 147.3 Malignant neoplasm of 
anterior wall of 
nasopharynx 
Head & Neck Cancer  1478 147.8 Malignant neoplasm of 
other specified sites of 
nasopharynx 
Head & Neck Cancer  1479 147.9 Malignant neoplasm of 
nasopharynx, unspecified 
site 
Head & Neck Cancer  148 148 Malignant neoplasm of 
hypopharynx 
Head & Neck Cancer  1480 148.0 Malignant neoplasm of 
postcricoid region of 
hypopharynx 
Head & Neck Cancer  1481 148.1 Malignant neoplasm of 
pyriform sinus 
Head & Neck Cancer  1482 148.2 Malignant neoplasm of 
aryepiglottic fold, 
hypopharyngeal aspect 
Head & Neck Cancer  1483 148.3 Malignant neoplasm of 
posterior hypopharyngeal 
wall 
Head & Neck Cancer  1488 148.8 Malignant neoplasm of 
other specified sites of 
hypopharynx 
Head & Neck Cancer  1489 148.9 Malignant neoplasm of 
hypopharynx, unspecified 
site 
Head & Neck Cancer  149 149 Malignant neoplasm of 
other and ill-defined sites 
within the lip, oral cavity, 
and pharynx 
Head & Neck Cancer  1490 149.0 Malignant neoplasm of 
pharynx, unspecified 
Head & Neck Cancer  1491 149.1 Malignant neoplasm of 
Waldeyer's ring 
Head & Neck Cancer  1498 149.8 Malignant neoplasm of 
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TUMOR TYPE TUMOR 
SUB-TYPE 
CODE CODE DESCRIPTION 
other sites within the lip and 
oral cavity 
Head & Neck Cancer  1499 149.9 Malignant neoplasm of ill-
defined sites of lip and oral 
cavity 
Gastrointestinal Cancers; 
Other 
Esophageal 
Cancer 
150 150 Malignant neoplasm of 
esophagus 
Gastrointestinal Cancers; 
Other 
Esophageal 
Cancer 
1500 150.0 Malignant neoplasm of 
cervical esophagus 
Gastrointestinal Cancers; 
Other 
Esophageal 
Cancer 
1501 150.1 Malignant neoplasm of 
thoracic esophagus 
Gastrointestinal Cancers; 
Other 
Esophageal 
Cancer 
1502 150.2 Malignant neoplasm of 
abdominal esophagus 
Gastrointestinal Cancers; 
Other 
Esophageal 
Cancer 
1503 150.3 Malignant neoplasm of 
upper third of esophagus 
Gastrointestinal Cancers; 
Other 
Esophageal 
Cancer 
1504 150.4 Malignant neoplasm of 
middle third of esophagus 
Gastrointestinal Cancers; 
Other 
Esophageal 
Cancer 
1505 150.5 Malignant neoplasm of 
lower third of esophagus 
Gastrointestinal Cancers; 
Other 
Esophageal 
Cancer 
1508 150.8 Malignant neoplasm of 
other specified part of 
esophagus 
Gastrointestinal Cancers; 
Other 
Esophageal 
Cancer 
1509 150.9 Malignant neoplasm of 
esophagus, unspecified site 
Gastrointestinal Cancers; 
Other 
Stomach 
Cancer 
151 151 Malignant neoplasm of 
stomach 
Gastrointestinal Cancers; 
Other 
Stomach 
Cancer 
1513 151.3 Malignant neoplasm of 
fundus of stomach 
Gastrointestinal Cancers; 
Other 
Stomach 
Cancer 
1514 151.4 Malignant neoplasm of 
body of stomach 
Gastrointestinal Cancers; 
Other 
Stomach 
Cancer 
1515 151.5 Malignant neoplasm of 
lesser curvature of stomach, 
unspecified 
Gastrointestinal Cancers; 
Other 
Stomach 
Cancer 
1516 151.6 Malignant neoplasm of 
greater curvature of 
stomach, unspecified 
Gastrointestinal Cancers; 
Other 
Stomach 
Cancer 
1518 151.8 Malignant neoplasm of 
other specified sites of 
stomach 
Gastrointestinal Cancers; 
Other 
Stomach 
Cancer 
1519 151.9 Malignant neoplasm of 
stomach, unspecified site 
Colorectal Cancer (CRC)  153 153 Malignant neoplasm of 
colon 
Colorectal Cancer (CRC)  1530 153.0 Malignant neoplasm of 
hepatic flexure 
Colorectal Cancer (CRC)  1531 153.1 Malignant neoplasm of 
transverse colon 
Colorectal Cancer (CRC)  1532 153.2 Malignant neoplasm of 
descending colon 
Colorectal Cancer (CRC)  1533 153.3 Malignant neoplasm of 
sigmoid colon 
Colorectal Cancer (CRC)  1534 153.4 Malignant neoplasm of 
cecum 
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TUMOR TYPE TUMOR 
SUB-TYPE 
CODE CODE DESCRIPTION 
Colorectal Cancer (CRC)  1535 153.5 Malignant neoplasm of 
appendix 
Colorectal Cancer (CRC)  1536 153.6 Malignant neoplasm of 
ascending colon 
Colorectal Cancer (CRC)  1537 153.7 Malignant neoplasm of 
splenic flexure 
Colorectal Cancer (CRC)  1538 153.8 Malignant neoplasm of 
other specified sites of large 
intestine 
Colorectal Cancer (CRC)  1539 153.9 Malignant neoplasm of 
colon, unspecified site 
Colorectal Cancer (CRC)  154 154 Malignant neoplasm of 
rectum, rectosigmoid 
junction, and anus 
Colorectal Cancer (CRC)  1540 154.0 Malignant neoplasm of 
rectosigmoid junction 
Colorectal Cancer (CRC)  1541 154.1 Malignant neoplasm of 
rectum 
Colorectal Cancer (CRC)  1548 154.8 Malignant neoplasm of 
other sites of rectum, 
rectosigmoid junction, and 
anus 
Pancreatic Cancer  157 157 Malignant neoplasm of 
pancreas 
Pancreatic Cancer  1570 157.0 Malignant neoplasm of head 
of pancreas 
Pancreatic Cancer  1571 157.1 Malignant neoplasm of 
body of pancreas 
Pancreatic Cancer  1572 157.2 Malignant neoplasm of tail 
of pancreas 
Pancreatic Cancer  1573 157.3 Malignant neoplasm of 
pancreatic duct 
Pancreatic Cancer  1574 157.4 Malignant neoplasm of 
islets of Langerhans 
Pancreatic Cancer  1578 157.8 Malignant neoplasm of 
other specified sites of 
pancreas 
Pancreatic Cancer  1579 157.9 Malignant neoplasm of 
pancreas, part unspecified 
Head & Neck Cancer  160 160 Malignant neoplasm of 
nasal cavities, middle ear, 
and accessory sinuses 
Head & Neck Cancer  1600 160.0 Malignant neoplasm of 
nasal cavities 
Head & Neck Cancer  1601 160.1 Malignant neoplasm of 
auditory tube, middle ear, 
and mastoid air cells 
Head & Neck Cancer  1602 160.2 Malignant neoplasm of 
maxillary sinus 
Head & Neck Cancer  1603 160.3 Malignant neoplasm of 
ethmoidal sinus 
Head & Neck Cancer  1604 160.4 Malignant neoplasm of 
frontal sinus 
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TUMOR TYPE TUMOR 
SUB-TYPE 
CODE CODE DESCRIPTION 
Head & Neck Cancer  1605 160.5 Malignant neoplasm of 
sphenoidal sinus 
Head & Neck Cancer  1608 160.8 Malignant neoplasm of 
other sites of nasal cavities, 
middle ear, and accessory 
sinuses 
Head & Neck Cancer  1609 160.9 Malignant neoplasm of site 
of nasal cavities, middle ear, 
and accessory sinus, 
unspecified site 
Head & Neck Cancer  161 161 Malignant neoplasm of 
larynx 
Head & Neck Cancer  1610 161.0 Malignant neoplasm of 
glottis 
Head & Neck Cancer  1611 161.1 Malignant neoplasm of 
supraglottis 
Head & Neck Cancer  1612 161.2 Malignant neoplasm of 
subglottis 
Head & Neck Cancer  1613 161.3 Malignant neoplasm of 
laryngeal cartilages 
Head & Neck Cancer  1618 161.8 Malignant neoplasm of 
other specified sites of 
larynx 
Head & Neck Cancer  1619 161.9 Malignant neoplasm of 
larynx, unspecified site 
Lung Cancer  162 162 Malignant neoplasm of 
trachea, bronchus, and lung 
Lung Cancer  1620 162.0 Malignant neoplasm of 
trachea 
Lung Cancer  1622 162.2 Malignant neoplasm of 
main bronchus 
Lung Cancer  1623 162.3 Malignant neoplasm of 
upper lobe, bronchus, or 
lung 
Lung Cancer  1624 162.4 Malignant neoplasm of 
middle lobe, bronchus, or 
lung 
Lung Cancer  1625 162.5 Malignant neoplasm of 
lower lobe, bronchus, or 
lung 
Lung Cancer  1628 162.8 Malignant neoplasm of 
other parts of bronchus or 
lung 
Lung Cancer  1629 162.9 Malignant neoplasm of 
bronchus and lung, 
unspecified site 
Malignant Neoplasms, Other  163 163 Malignant neoplasm of 
pleura 
Malignant Neoplasms, Other  1630 163.0 Malignant neoplasm of 
parietal pleura 
Malignant Neoplasms, Other  1631 163.1 Malignant neoplasm of 
visceral pleura 
Malignant Neoplasms, Other  1638 163.8 Malignant neoplasm of 
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TUMOR TYPE TUMOR 
SUB-TYPE 
CODE CODE DESCRIPTION 
other specified sites of 
pleura 
Malignant Neoplasms, Other  1639 163.9 Malignant neoplasm of 
pleura, unspecified site 
Malignant Melanoma  1720 172.0 Malignant melanoma of 
skin of lip 
Basal Cell Carcinoma  17301 173.01 Basal Cell Carcinoma Of 
Skin Of Lip 
Gynecological Cancer Cervical 
Cancer 
180 180 Malignant neoplasm of 
cervix uteri 
Gynecological Cancer Cervical 
Cancer 
1800 180.0 Malignant neoplasm of 
endocervix 
Gynecological Cancer Cervical 
Cancer 
1801 180.1 Malignant neoplasm of 
exocervix 
Gynecological Cancer Cervical 
Cancer 
1808 180.8 Malignant neoplasm of 
other specified sites of 
cervix 
Gynecological Cancer Cervical 
Cancer 
1809 180.9 Malignant neoplasm of 
cervix uteri, unspecified site 
Ovarian Cancer  183 183 Malignant neoplasm of 
ovary and other uterine 
adnexa 
Ovarian Cancer  1830 183.0 Malignant neoplasm of 
ovary 
Gynecological Cancer  1838 183.8 Malignant neoplasm of 
other specified sites of 
uterine adnexa 
Gynecological Cancer  1839 183.9 Malignant neoplasm of 
uterine adnexa, unspecified 
site 
Bladder Cancer  188 188 Malignant neoplasm of 
bladder 
Bladder Cancer  1880 188.0 Malignant neoplasm of 
trigone of urinary bladder 
Bladder Cancer  1881 188.1 Malignant neoplasm of 
dome of urinary bladder 
Bladder Cancer  1882 188.2 Malignant neoplasm of 
lateral wall of urinary 
bladder 
Bladder Cancer  1883 188.3 Malignant neoplasm of 
anterior wall of urinary 
bladder 
Bladder Cancer  1884 188.4 Malignant neoplasm of 
posterior wall of urinary 
bladder 
Bladder Cancer  1885 188.5 Malignant neoplasm of 
bladder neck 
Bladder Cancer  1886 188.6 Malignant neoplasm of 
ureteric orifice 
Bladder Cancer  1887 188.7 Malignant neoplasm of 
urachus 
Bladder Cancer  1888 188.8 Malignant neoplasm of 
other specified sites of 
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TUMOR TYPE TUMOR 
SUB-TYPE 
CODE CODE DESCRIPTION 
bladder 
Bladder Cancer  1889 188.9 Malignant neoplasm of 
bladder, part unspecified 
Kidney Cancer, Other  189 189 Malignant neoplasm of 
kidney and other and 
unspecified urinary organs 
Renal Cancer  1890 189.0 Malignant neoplasm of 
kidney, except pelvis 
Kidney Cancer, Other  1891 189.1 Malignant neoplasm of 
renal pelvis 
Kidney Cancer, Other  1892 189.2 Malignant neoplasm of 
ureter 
Genitourinary Cancer  1893 189.3 Malignant neoplasm of 
urethra 
Genitourinary Cancer  1894 189.4 Malignant neoplasm of 
paraurethral glands 
Genitourinary Cancer  1898 189.8 Malignant neoplasm of 
other specified sites of 
urinary organs 
Genitourinary Cancer  1899 189.9 Malignant neoplasm of 
urinary organ, site 
unspecified 
Leukemia Acute 
Myeloid 
Leukemia 
(AML) 
2050 205.0 Acute myeloid leukemia 
Leukemia Acute 
Myeloid 
Leukemia 
(AML) 
20500 205.00 Acute myeloid leukemia 
without mention of 
remission 
Leukemia Acute 
Myeloid 
Leukemia 
(AML) 
20501 205.01 Acute myeloid leukemia in 
remission 
Leukemia Acute 
Myeloid 
Leukemia 
(AML) 
20502 205.02 Acute myeloid leukemia, in 
relapse 
Endocrine Cancer  20921 209.21 Malignant carcinoid tumor 
of the bronchus and lung 
Endocrine Cancer Stomach 
Cancer 
20923 209.23 Malignant carcinoid tumor 
of the stomach 
Endocrine Cancer  20924 209.24 Malignant carcinoid tumor 
of the kidney 
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Table A.3.2.  Results of Test for Multicollinearity Among Independent Variables 
Selected for Multivariate Logistic Regression – Predictors of SCM Use in 
Tobacco Dependent Patients with Smoking Related Cancer 
 
Regression Against Patient Age at Index 
Independent Variable Variance Inflation Factor Condition Index 
Charlson Co-morbidity Index Score 
in 12 months pre-index 
1.067 1.889 
Insurance Product HMO 1.136 1.991 
Payer Type Commercial 2.896 2.111 
Payer Type Medicaid 1.747 2.188 
Payer Type Medicare Supplemental 1.187 2.321 
Payer Type Medicare Advantage 1.960 2.665 
Payer Type Self-insured 1.859 2.754 
Diagnosing Practitioner Type 
Hospital Related 
3.581 3.177 
Diagnosing Practitioner Type 
General Medicine 
3.632 5.247 
Diagnosing Practitioner Type 
Therapeutic Area Specialist 
2.254 7.809 
Diagnosing Practitioner Type Other 1.400 14.917 
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